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La miopatia nemalinica (NM) è un disordine neuromuscolare caratterizzato da 
debolezza muscolare e ipotonia in seguito a disorganizzazione sarcomerica e alla 
formazione di corpi “nemalinici”nelle fibre muscolari. La patologia colpisce 1 su 
50000 nati vivi ed è causata da mutazioni delle proteine nebulina e α-actina mentre 
mutazioni in α-tropomiosina, β-tropomiosina, troponina T1 e cofilina-2 sono più 
rare. Al momento non esistono né terapie né marker della malattia. In pazienti NM 
è stata riportata l’alterazione di geni coinvolti in meccanismi secondari. Allo stesso 
tempo è stata mostrata la de-regolazione di diversi microRNAs (miRs) in muscoli di 
pazienti NM. Basandoci su questi dati riportati in letteratura, abbiamo ipotizzato 
l’esistenza di meccanismi specifici, regolati da miRs, che potrebbero sottendere 
alla patologia, indipendentemente dal gene malattia. Per studiare questi, abbiamo 
utilizzato un topo modello di NM transgenico knockin, che esprime una forma 
mutata della α-actina, (Acta1(H40Y)KI) (KI), che sviluppa una forma grave di NM. 
Mentre i maschi KI muoiono a circa 11 settimane di vita, le femmine esibiscono un 
fenotipo più lieve e sono fertili. 
Il primo scopo del nostro studio era studiare l’espressione genica del diaframma 
(DIA) e del tibiale anteriore (TA) in topi KI e paragonare i risultati con quelli 
precedentemente pubblicati dell’analisi di espressione genica di pazienti NM e del 
topo Tmslow(Met9Arg) Tg (Tg), topo modello di una forma più lieve di NM. Il 
secondo scopo era paragonare il profilo di espressione genica tra maschi e 
femmine KI, per comprendere le basi molecolari per la differente severità della 
patologia. Il terzo scopo era studiare il profillo di espressione dei miRs in topi KI 
maschi, in uno stadio precoce e tardivo della patrologia, per indagare l’espressione 
dei miRs in relazione allo sviluppo della patologia. 
Lo studio di espressione genica è stato condotto su maschi di 3 settimane e 
maschi e femmine di 10 settimane. I maschi giovani presentavano la più alta de-
regolazione genica. Solo pochi geni de-regolati erano in comune tra DIA e TA, 
probabilmente a causa di un profilo di espressione genica peculiare del DIA. Tra le 
differenti condizioni, le femmine in stadio tardivo avevano un profilo di espressione 
genica più simile ai maschi in uno stadio precoce, che ai maschi in uno stadio 
tardivo, riflettendo uno sviluppo ritardato del fenotipo. Comunque, anche se nello 
specifico i geni de-regolati erano diversi, gli stessi meccanismi erano affetti nelle 
differenti condizioni. Alcuni di questi, ad esempio i meccanismi metabolici, sono 
stati trovati de-regolati anche in pazienti NM, ma non in topi Tg. 
I topi KI mostravano livelli alterati dei miRs selezionati, parallelamente a quanto 
riportato in uomo, ma i topi Tg non mostravano la stessa de-regolazione. Il miR-
381 è stato trovato espresso ad alti livelli nel KI e due dei suoi putativi targets sono 
stati confermati in vitro tramite saggio di luciferasi: una proteina dei canali del 
calcio (TRPM7) e una proteina coinvolta nel sistema dell’ubiquitina 
(Trim63/MURF1). 
I risultati di questo studio indicano che Acta1(H40Y)KI è un buon sistema modello 
per lo studio della NM, sia da un punto di vista fenotipico che genetico. Questo 
modello è migliore del topo Tg, dal momento che presenta profili di espressione 
genica e di miR più simili all’uomo. Il significato biologico dei meccanismi genici 
alterati e la loro possibile regolazione ad opera dei miRs restano da essere studiati 
più a in dettaglio. 
II 
 
Nemaline myopathy (NM) is a clinically and genetically heterogeneous 
neuromuscular disorder characterized by muscle weakness and hypotonia due to 
sarcomeric disarray and the formation of rod-like "nemaline" bodies in the muscle 
fibers. The disease affects about 1 in 50.000 and is caused by mutations in nebulin 
and α-skeletal muscle actin, while mutations in α-tropomyosin, β-tropomyosin, 
troponin T1, and cofilin-2 are more rare. Currently no therapies or markers exist. 
Gene expression profiling has provided insights into the gene expression changes 
associated with NM in human patients. Furthermore, a number of microRNAs 
(miRs) have been shown to be specifically dysregulated in muscles from NM 
patients. Based on these findings, we hypothesized that unique regulatory 
mechanisms regulated by miRs may underlie the pathology of NM irrespective of 
the causative mutation. To study this, we took advantage of a transgenic knockin 
mouse model of NM, expressing a mutant form of α-skeletal actin (Acta1(H40Y)KI) 
(KI) that develops a severe form of the disease. Interestingly, while KI males exhibit 
a severe phenotype resulting in death from around 10 weeks of age, females are 
less severely affected and are fertile.  
The first aim of our study was to perform gene expression profiling on diaphragm 
(DIA) and tibialis anterior (TA) muscle of KI mouse and compare the results with 
previously published gene expression analyses of NM patients and the 
Tmslow(Met9Arg) Tg (Tg) mouse model of a mild form of NM. The second aim was 
to compare the gene expression profile of male and female KI mice to provide 
insights into the molecular basis for the different severity of the disease in males 
and females. The third aim was to investigate the miR expression profile in KI 
males at an early and late stage of the disease to study miR expression in relation 
to the development of the disease. 
The gene expression study was conducted on 3-week-old males and 10-week-old 
males and females. The highest number of dysregulated genes were found in 3-
week-old males. Between muscles (DIA and TA) only few altered genes were in 
common, possibly due to a peculiar gene expression pattern of the DIA. 
Interestingly, 10-week-old females showed a gene expression pattern more similar 
to 3-week-old males than to 10-week-old males, reflecting a delay in the 
development of the phenotype. However, although the specific dysregulated genes 
were different, some pathways were commonly dysregulated under different 
conditions. The same pathways, i.e. metabolic pathways, were found to be 
dysregulated in KI and human NM patients, but not in Tg mice. 
Expression levels of selected miRs that are altered in human NM patients were 
also altered in KI mice, but not in Tg mice. MiR-381 was highly upregulated and 
two of its predicted targets were validated in vitro by a luciferase assay: the calcium 
channel protein TRPM7 and the ubiquitin-related protein Trim63/MURF1. 
The results of this study indicate that Acta1(H40Y)KI is a good model of NM that 
recapitulates NM disease from both a phenotypic and genetic point of view. It is a 
better model for NM than the Tg mouse, showing gene and miR expression 
patterns more similar to NM patients. The biological meaning of the altered gene 
expression patterns and their possible regulation by miRs remain to be investigated 
in more detail. 
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RNA – ribonucleic acid  
miR – microRNA 
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TA – Tibialis Anterior 
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KNG – kininogen 
KNG2 – kininogen2 
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Sepp1 - selenoprotein P1 
ACAA2 - acetyl-coenzyme A acyltransferase 2 
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MRPL20 - mitochondrial ribosomal protein L20 
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Bmp4 - bone morphogenetic protein 4 
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Foxo1 - forkhead box O1 
Lep – leptin 
Map3k6  - mitogen-activated protein kinase kinase kinase 6 
Phlda3 - pleckstrin homology-like domain, family A, member 3 
Spsb1 - splA/ryanodine receptor domain and SOCS box containing 1 
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Cdc34 - cell division cycle 34 homolog 
Ptpre - protein tyrosine phosphatase, receptor type, E 
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1.INTRODUCTION 
1.1 Skeletal muscle 
1.1.1 Skeletal muscle structure 
Skeletal muscle is a form of striated muscle composed of tissue, connective tissue, 
nerves and blood vessels (fig.1). The individual components of skeletal muscle are 
muscle fibers (approximately 50 μm in diameter and up to several centimeters in 
length), cylindrical multinucleated cells formed by the fusion of developmental 
myoblasts (muscle cell progenitors). This differentiation process occurs before birth 
and cells continue to grow in size thereafter. The striation seen in skeletal muscle 
cells is the consequence of a peculiar cytoskeletal organization: two cytoplasmic 
proteins, actin and myosin (also known as "thick" and "thin" filaments, respectively) 
are arranged in repeating units called sarcomeres. The sliding of filaments along 
each other is responsible for muscle contraction. 
 
Skeletal muscle fibers can be classified based on the type of myosin and on their 
metabolism. There are two main classes of fiber types, slow twitch (Type I) and fast 
twitch (Type II) muscle fibers. Type I fibers are highly resistant to fatigue and show 
extended muscle contraction over a long time. From the biochemical point of view 
they present oxidative enzymes, low glycolytic markers, and ATPase activity. Type 
II fibers use anaerobic metabolism and contract faster, fatiguing more quickly. 
Biochemically they present high oxidative and glycolytic enzymes and ATPase 
activity. Type II fibers can be further grouped into different subtypes, depending on 
the myosin heavy chain isoform (MHC): type IIa, IIx, and IIb. In human, only type 
IIa and IIx fiber are present, while in small mammals type IIb is the major fast 
muscle isoform. MHCIIx (or MHCIId) was later identified in small mammals and 
based on DNA analysis, it is the homologue of the MHCIIb originally identified in 
humans. This finding has caused confusion in the literature, and sometimes human 
fiber type IIx is referred to as type IIb based on the original MHC nomenclature. 
Type IIa fibers are also known as intermediate fast-twitch fibers. They are able to 
use aerobic and anaerobic metabolism, and are considered intermediate because 
do not maintain a great amount of their force production with repeated activity. The 
Type IIb/IIx fibers are the “classic” fast twitch fibers, using anaerobic metabolism, 
and having a faster rate of fatigue. Different muscles are a mixture of different fiber 
types and their percentage vary depending on the action of that muscle.  
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Fig.1 schematic representation of skeletal muscle 
 
 
1.1.2 The sarcomere 
The four major functional characteristics of muscle are excitability (it responds to 
stimulation by nerves and hormones), extensibility (it can be stretched), elasticity 
(after stretching it recoils to the original resting length), and contractility. The 
contractile functional unit of the skeletal muscle is the sarcomere (approximately 
2.3 μm long), which gives the muscle its striated appearance visible by light 
microscopy as three major bands: A, I, and Z (fig.2). The A-band is composed of 
thick filaments (myosin) and proteins bound to myosin; the middle part of the A-
band is named the “M-band” or “M-line”. The I-band is made up of thin (actin) 
filaments and actin-binding proteins. In the middle of the I-band between two 
neighboring sarcomeres is the Z-disc, or Z-line. The protein composition of the Z-
line is heterogeneous: channels, cytoplasmatic, and nuclear signaling molecules, 
enzymes, and cytoskeletal proteins, colocalize together, conferring a 
multifunctional nature to the Z-band [
1
,
2
,
3
]. 
 
The interdigitating actin (thin) and myosin (thick) filaments slide past each other 
during muscle contraction. The thin filament can polymerize and depolymerize and 
thus presents a fast-growing end called the “barbed end”, and a slow-growing end 
called the “pointed end”. Since the movement of myosin motors is unidirectional, 
contractile force can be produced because of the orientation of thin filaments in 
opposite directions at each end of the sarcomere. α-actinin plays a role in 
stabilizing the right polarization of the thin filament, cross-linking actin filaments 
near their barbed ends in the Z-band, while their pointed ends are not bound to any 
particular structure. The cytoskeletal reorganization in which actin is involved in 
vivo is too fast to be supported only by the actin turnover rate; thus there are 
several actin-binding proteins that regulate actin filament turnover by promoting 
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polymerization, depolymerization, or filament severing [
4
, 
5
, 
6
]. Among these, 
ADF/cofilin and gelsolin are actin-severing proteins: ADF/cofilin promotes actin 
monomer dissociation from the pointed end [
7
] and gelsolin caps the barbed end in 
a calcium-dependent manner [
8
, 
9
] (its role in regulation of actin has to be better 
elucidated). Actin filament stability is maintained through the action of side-binding 
proteins, such as tropomyosin that is also involved in the regulation of muscle 
contraction [
10
]. It has been reported that tropomyosin spontaneously inhibits actin 
polymerization and depolymerization in vitro [
11
, 
12
, 
13
, 
14
], and protects actin 
filament from the severing action of ADF/cofilin and gelsolin [
15
, 
16
, 
17
,
18
].  
 
A third filament system is formed by the giant protein, titin, which act as a spring by 
keeping the thick filament centered during contraction and is thought to function in 
signaling pathways and dictate the assembly of other sarcomeric components. In 
skeletal muscle, a fourth filament system is formed by the giant modular protein, 
nebulin (600-800 kDa), which is associated with and spans along the thin filament 
in skeletal muscle with its C-terminus anchored in the Z-line and its N-terminus 
extending towards the thin filament pointed end [
19
]. In cardiac muscle, a smaller 
nebulin-like protein, nebulette (107 kDa), is expressed and may have overlapping 
functions with nebulin in the Z-line, suggesting that it covers an important role in 
the sarcomere [
20
, 
21
]. In the past years, in vitro studies on nebulin depletion have 
suggested a role of nebulin in regulating thin filament length (“nebulin ruler” 
hypothesis) [
22
, 
23
]. Recently, Castillo et al. observed that in rabbit skeletal muscle, 
nebulin does not extend to the pointed ends [
24
]. Furthermore, in nebulin-deficient 
mice, thin filaments are assembled with uniform but shorter length than in wildtype 
neonatal skeletal muscle, becoming more variable in length during postnatal 
development [
25
, 
26
]. Likewise, human patients affected by Nemaline Myopathy 
caused by nebulin mutations also exhibited shorter thin filament lengths [
27
]. Taken 
together, these findings show that thin filament lengths are still regulated in the 
absence of nebulin, suggesting that nebulin alone does not determine thin filament 
length. More recently, functional studies have strongly suggested that nebulin is a 
regulator of the dynamic exchange of actin subunits and other thin filament 
proteins. This is supported by the binding of nebulin to the barbed end capping 
protein, CapZ [
28
] as well as to the pointed end capping protein, tropomodulin [
29
]. 
Moreover Pappas et al. have shown that nebulin stabilizes sarcomeric thin 
filaments, not only by inhibiting actin depolymerization but also by stabilizing other 
thin filament proteins, such as tropomyosin and tropomodulin [
30
]. 
 
Several myopathies are caused by mutations in genes encoding thin filament or Z-
line proteins. Nemaline Myopathy (NM), which is classified as a non-dystrophic 
skeletal muscle myopathy, is one of them, caused by mutations in six different thin 
filament proteins: α-actin, nebulin, troponin-T, cofilin-2, tropomyosin-1, and 
tropomyosin-3. Recently, studies have suggested alterations in adult stem cell 
myogenesis and the cross-bridge cycle in NM. These NM-related aspects are 
discussed in chapter 1.2, while the next paragraphs report the most recent findings 
regarding myogenesis and contractility mechanisms in normal muscle.  
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Schematic representation of the sarcomere and proteins associated to the Z-
band (Sanger and Sanger, Science signaling, 2008) 
 
1.1.3 Myogenesis 
1.1.3.1 Genetics of the developmental myogenesis 
The skeletal muscles of the trunk and the limbs originate from a subset of the 
paraxial mesoderm called somites. The somites are epithelial structures that result 
from the segmentation of the presomitic mesoderm. These structures begin to form 
at the anterior of the embryo and are added posteriorly as the embryo extends. 
During the development the somites form distinct compartments from which distinct 
tissues of the animal will originate. The compartments are the sclerotome (origin of 
vertebrae and ribs), the dermatome (origin of dorsal dermis), the syndetome (origin 
of axial tendons), and the myotome (origin of the muscle differentiation) [
31
, 
32
]. 
Before the compartmentalization in dermatome and myotome, a unique „C‟-shaped 
epithelial structure exists in which myogenic and dermal progenitors can first be 
detected, called the dermomyotome. 
The myogenic precursors are labeled by the paired box transcription factors PAX3 
and PAX7, that are induced by exogenous signals [
36
] to be highly expressed and 
regulate the start of the myogenic programmme in cooperation with other factors, 
such as DACH2, SIX1, and EYA2 proteins [
37
, 
38
, 
39
].    
As soon as the myogenic cells are labeled by PAX3 and PAX7, they migrate 
around the edges of the dermomyotome, giving rise to the specific myotome 
compartment. At this point, the muscle specific markers are expressed while PAX3 
is downregulated and PAX-7 expression is retained only in the satellite cells (adult 
stem muscle cells) [
40
, 
41
, 
42
]. This is the crucial point of myogenesis, in which there 
is a switch from proliferation to differentiation, from myoblast to post mitotic 
myocytes. The first marker of differentiation is Myf5, followed by MyoD. At later 
stages, cells from the central dermomyotome can either self-renew and remain in 
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the epithelial border of the dermomyotome or migrate to the myotome [
33
, 
34
, 
35
], 
forming the satellite cells that are the adult muscle stem cells [
40
, 
43
, 
44
]. However it 
is not yet clear how the migration of the central dermomyotome  cells is regulated. 
The limb muscles and the trunk muscles don‟t follow exactly the same myogenic 
programme.Here limb muscle myogenesis is illustrated, reporting the last findings 
in the field. 
The first steps of myogenesis have recently been shown to be promoted by a short 
activation of NOTCH signaling [
45
]. NOTCH signalling displays a complex behavior 
on myogenesis, acting as a potent stimulator of the myogenic program for DML 
cells (cells of the dorsomedial lip), but only during a limited time window. In fact a 
sustained activation of NOTCH reverses the myogenic program, resulting in 
downregulation of MRF (myogenic regulatory factor) expression and a return to a 
PAX7-positive state. Transient activation of the NOTCH signaling pathway has 
been shown to be fundamental for the initiation of myogenesis [
45
] and to be 
induced by the interaction of muscle progenitor cells with a ligand (DLL1) exposed 
on neural crest cells. A model of a „kiss and run‟ mode of signaling transduction 
has been suggested, in which there is a rapid interaction between muscle 
progenitor cells and neural crest cells. Moreover this links the timing of myotome 
formation to that of neural crest migration, providing a mechanistic link for the 
concurrence of these two events [
45
]. 
Subsequent to NOTCH signaling the MRFs, including Myf5, MyoD, Mrf4 
(sometimes referred to as Myf6), and myogenin, are activated. These proteins 
have distinct functions and cooperate in inducing the expression between each 
other. It has been reported that they are partially redundant so that the loss of one 
MRF member can be compensated for by the upregulation of another [
46
]. Myf5 
acts at the top of the myogenic cascade and its expression is regulated by a 
multiple enhancer controlled pathway. The other MRFs are often induced by the 
expression activation of another MRF. It is possible that this self-reinforcing 
mechanism is required to lock down the myogenic programme and inactivate other 
differentiation programmes [
47
, 
48
, 
49
]. 
Although the interactions between MRFs are complex, mouse mutants have given 
some indication of specific functions of individual MRFs. Myogenin-null mice die at 
birth due to a severe deficiency in myoblast differentiation [
50
], while mice carrying 
mutations in Myf5, MyoD, or Mrf4 are viable and produce morphologically normal 
muscle. On the other hand, simultaneous lack of all three genes causes muscle 
defects at embryonic stage [
51
 , 
52
]. Taken together, these findings indicate a high 
degree of plasticity and the presence of compensatory mechanisms that are able to 
induce myogenesis even when normal mechanisms are severely compromised. 
Recent studies have suggested that non-MRF-dependent mechanisms exist that 
can lead to muscle differentiation [
53
, 
54
]. For example it has been shown that MRFs 
can be bypassed altogether in some muscle stem cells and that Pax3 alone can 
drive differentiation in these cells [
53
]. 
1.1.3.2 Genetics of the regenerative myogenesis  
During muscle injury and under pathological conditions (i.e. muscular dystrophy)  
occurs the degeneration of myofibers. Consequently, the satellite cells, the adult 
stem cell of the skeletal muscle, present at the basal lamina of the myofibers, are 
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activated to, differentiate and fuse with each other or preexisting myofibers to 
regenerate the muscle [
55
, 
56
]. Satellite cells are classified as stem cells since 
following injury some fraction of them self-renew, contributing to the maintenance 
of the quiescent satellite cell pool. It has recently been shown that only one single 
satellite cell is able to self-renew and differentiate when transplanted in an injured 
muscle [
57
]. 
It is thought that the cellular mechanisms at the basis of developmental, postnatal, 
and adult regenerative myogenesis are similar. However, in the last years some 
differences in the genetics for embryonic, fetal, postnatal, and adult regenerative 
myogenesis have been reported. For example, while myogenin-null mice have 
defects in developmental myogenesis, myogenin deficient satellite cells form 
myotubes normally in vitro, and an altered pattern of gene expression is present in 
myogenin-conditionally-deleted muscle in vivo [
50
, 
58
]. However the ability of adult 
myogenin-null mice to repair muscle injury has not yet been assessed.  
Pax7 is expressed in all adult satellite cells and is required for their maintenance in 
the postnatal period [
59
]; Pax7-null mice show severe defects in regenerative 
myogenesis [
60
, 
61
]. Surprisingly, when Pax7 is removed after three weeks of age, 
no defects are reported in limb muscle regeneration [
62
], suggested also in this 
case a difference in developmental and regenerative myogenesis programmes. 
1.1.4 Muscle contraction 
One of the major characteristics of striated muscle is the ability to contract, owing 
to the presence of the functional contractile unit, the sarcomere. Contraction occurs 
by the “sliding mechanism” when thick (myosin) and the thin (actin) filaments are 
mutually sliding over each other [
63
, 
64
]. The length of the thick and thin filaments is 
unchanged before and after shortening of the muscle. In the thick-thin filament 
overlapping region, bridge-like structures (actin-myosin interaction) called “cross-
bridges” can be identified, as responsible for the movement and force developed 
during contraction [
65
, 
66
]. It is known that ATP is involved in muscle contraction, 
serving at least two functions: first, ATP disconnects actin from myosin, and 
second, ATP is hydrolyzed by the myosin molecule to produce the energy required 
for muscle contraction [
67
]. The structure of the globular head of the myosin 
(myosin S1 region) has been revealed by X-ray diffraction [
68
] and appears like a 
“back door” enzyme, in which the ATP (substrate) and actin (catalyst) bind on 
opposite sites of the molecule. These observations have provided the basis for a 
molecular mechanism by which ATP binding leads to actin dissociation and force 
generation. In the steady-state, myosin and actin are tightly bound to each other 
and the long cleft connecting ATP to the actin binding site is “closed”. This cleft is 
opened after the binding of ATP to myosin, causing changes in the shape of S-1. 
Cleft opening disrupts the interaction between actin and myosin so that myosin 
“lets go” of the actin filament. ATP is hydrolyzed and ADP and Pi are released, 
chemical energy from ATP is transferred to the myosin molecule, and the cross-
bridge shows the “cocking” conformation. In the last step, actin rebinds to myosin 
and the terminal phosphate group of ATP is released. It is believed that this allows 
the myosin molecule to reverse the conformational changes while bound to actin, 
thus providing the power stroke of muscle contraction.  
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The mechanism described above is referred to as the activity of the contractile 
system of muscle under full activation (ON state). During relaxation the muscle is in 
OFF state. A calcium-dependent mechanism regulates the ON (contraction) - OFF 
(relaxation) states of the contractile system of muscle as an important part of the 
excitation-contraction (E–C) coupling pathway. The protein that binds to Ca
2+
 is 
troponin C, which is located in the thin filament. In the presence of ATP, the 
formation of force-generating cross-bridges is inhibited when troponin does not 
bind Ca
2+
[
69
, 
70
, 
71
]. However in the E–C coupling pathway there are several 
hierarchical feedback loops. Among the feedback regulations, mechano-electric 
feedback has been extensively investigated [
72
]. It is also well-known that the Ca
2+
 
binding to troponin induces cross-bridge formation, and conversely that the cross-
bridge formation enhances the Ca
2+
 binding affinity of troponin [
73
]. This is one of 
the reported feedback loops and it is supposed that also other feedback loops 
exist, such as in the regulation of Ca
2+
-release/uptake by the sarcoplasmic 
reticulum (SR) due to deformation of the SR by the force generated by the cross-
bridges. 
It has been reported that in the steady state conditions intermediate between full 
contraction and relaxation conditions, auto-oscillation of sarcomere length occurs. 
This phenomenon is called SPOC (SPontaneous Oscillatory Contraction of 
myofibrils) [
74
, 
75
]. Recently it has been suggested that even a molecular system 
composed of a small number of myosin molecules and a single actin filament is an 
auto-oscillator [
76
]. It is possible that the contractile system constituting a hierarchic 
structure from a molecular level, up to myofibrils and fibers having auto-oscillatory 
properties characteristic for each level of hierarchy [
77
]. 
1.2 Nemaline Myopathy 
1.2.1 Clinical features of Nemaline Myopathy 
Nemaline myopathy (NM), first described in the 1963 by Conen et al [
78
] and Shy et 
al.[
79
], is a slowly- or non-progressive neuromuscular disorder characterized by 
muscle weakness and the presence of rod-shaped structures called nemaline rods 
in affected muscle fibers, that give the name to the disease (nema being the Greek 
word for thread). Even if it is a rare disease, affecting 1 per 50000 live births, it is 
the most common of the non-dystrophic congenital myopathies. Many cases are 
sporadic, but the majority of NM cases exhibit either autosomal recessive or 
dominant patterns of inheritance. 
Patients affected by nemaline myopathy suffer from hypotonia and general muscle 
weakness, predominantly in facial muscles and finger extensor muscles. Moreover 
dysphagia, respiratory insufficiency, foot deformities, arched palate, scoliosis, chest 
deformities, and superior and inferior limbs contractures has been reported in NM 
patients. 
Currently, the NM forms are grouped into six classes [
80
]. In all the clinical forms, 
the central nervous system is unaffected, and intelligence and cardiac contractility 
are usually normal. 
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- The typical (i.e. most common) form of NM is usually autosomal recessive 
and present with congenital or infantile hypotonia, weakness, and often, 
feeding difficulties. Neonates that present profound weakness and 
hypotonia often improve their strength with age, delaying attainment of 
gross motor skills and starting later to walk. The gross motor activity is 
usually impaired in adult, while fine motor activity is normal. Patients are 
usually thin with a narrow face and a high arched palate; atrophy also 
occurs sometimes. Proximal muscles are generally more affected than 
distal ones, although distal weakness, especially later in life, is not 
uncommon. The most common problem in these patients, even in those 
less affected, is in breathing, since respiratory muscles are always 
involved, leading to nocturnal hypoxia and hypercarbia. Problems with the 
joints like hypermobility, deformities, or contracture are also common, 
occurring congenitally or occasionally in the later stages of NM. However 
many patients are able to conduct an active life and only in some cases a 
wheelchair is required. The eventual death is often due to respiratory 
insufficiency. 
- Mild NM: The difference from patients affected by the typical form is the 
childhood onset. Otherwise these patients show the same phenotype as 
the typical form, being indistinguishable from typical cases at later stages. 
From a genotypic point of view, mild NM is heterogeneous, counting 
sporadic case, autosomal recessive, and  also autosomal dominant cases. 
- Severe NM: Usually this form of the disease is sporadic, although in few 
cases autosomal recessive inheritance is reported. The major problem of 
the patients is respiratory insufficiency, resulting from a profound 
diaphragm and intercostals muscle weakness and hypotonia present in all 
the skeletal muscles. Death from respiratory insufficiency or pneumonia 
often occurs in the first months of life, and in general patients with severe 
NM never survive to reproduce. 
Difficulties in swallowing and sucking are often reported. Sometimes patients 
initially classified as “severe” survive with minimal residual disabilities and become 
classified as “intermediate” or “typical”.  
- Intermediate NM: Some patients cannot be classified as “typical”, even if 
they show typical presentations due to the progressive course of the 
disease. In the same way some patients presenting profound muscle 
weakness survive infancy and cannot be classified as “severe”. The 
characteristics of these “intermediate” cases are the survival past one year, 
the inability to sit and/or walk, or the loss of ambulation and progressive 
worsening by age of 11 years.  
- Adult onset NM: Some patients don‟t present any symptom before the 
third decade of life; it is possible that the onset of the disease occurs even 
later, until the sixth decade. Inflammatory changes are found in muscle 
biopsies of muscles affected by progressive weakness, suggesting that 
these cases might represent a distinctly different pathophysiological 
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mechanism. Others with only minimal muscle weakness present 
cardiomyopathy.  
- Amish NM: This is a clinically distinct autosomal recessive form described 
in only a single genetic isolate of related Old Order Amish families with 
neonatal onset. The symptoms are hypothonia, contractures, and tremors 
during the first 2-3 months of life. The severe pectus carinatum associated 
with muscle atrophy, progressive weakness, and contractures often leads 
to death at around 2 years of age owing to respiratory insufficiency. 
- Other forms of NM: Patients with nemaline rods, presenting atypical 
symptoms such as ophthalmoplegia, are included in this heterogeneous 
category. In relation to the pathophysiology, it is unclear whether it is right 
to categorize these cases as variants of NM or as other rods-associated 
diseases. 
 
Nemaline rods are the hallmarks of the disease and are revealed by the Gomori 
trichrome method on frozen sections. Some fibers exhibit size variation and 
predominance of type 1 fibers is a common feature of NM with some patients 
showing exclusively type 1 fibers or poor fiber type differentiation [
81
]. However, 
cases of patients with increased proportions of fast (type 2) fibers have also been 
reported. Fiber degereration/regeneration is not reported as a characteristic of NM, 
even though recently studies have shown signs of degeneration/regeneration in 
some patients as well as in a mouse model carrying a mutation in TPM3 gene.  
Recent studies based on the analysis of biopsies from NM patients and mouse 
models of NM have revealed that the weakness associated with NM may at least 
partly be due to a reduced number of actomyosin cross-bridges and in some cases 
also reduced thin filament length, suggesting the potential for developing future 
therapies targeted towards restoring the altered cross-bridge cycling kinetics 
1.2.2 The hallmarks of the NM: nemaline bodies 
Nemaline bodies (fig.3) are electron dense rods, measuring 1-7µm in length and 
0.3-2µm in width. They are in structural continuity with Z-disks and often 
associated with sarcomeric disarray and loss of registration [
82
, 
83
]. The presence of 
areas of complete sarcomeric disorganization close to relatively normal 
sarcomeres is quite frequent; this phenomenon is poorly understood. Nuclear 
nemaline bodies could be present as well. 
In human myopathies, there is no firm association between the number and 
location of the rods and the severity of muscle weakness or age at the onset [
92
]; a 
big variability in rod frequency in different skeletal muscles of different patients or 
within the same patient has been reported. These findings suggest that the disease 
phenotype is more influenced by variations in the underlying pathological 
processes that result in rods, rather than by the presence of rods themselves.  
The analysis of rod composition has revealed the presence of aggregates of thin 
filament proteins in nemaline bodies, mainly derived from the Z-line, including actin, 
-actinin 2, telethonin, -filamin, myozenin, myopalladin, and myotilin, but not 
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desmin. Rods are not only present in NM patients but are also observed in 
polymyositis, human immunodeficiency virus infection, and myofibrillar myopathy 
as well as in normal aging muscle, and not all of them show the same protein 
composition. They are generally formed in skeletal muscle under inflammation and 
degeneration as a pathophysiological response. Moreover, rods association with 
abnormal mitochondria have been described, and this pathology has been 
classified as nemaline-mitochondrial myopathy.  
It has been shown that is possible to induce in vitro rod formation in non-muscle 
and muscle cells [
84
] by using different cell stressors such as adenosine 
triphosphate (ATP) depletion, dimethyl sulfoxide, and heat shock. Furthermore, it 
has been suggested that metabolic alterations during formation and turnover of the 
sarcomere can lead to rod formation [
84
]. However the mechanisms underlying rod 
formation in skeletal muscle is still unclear, in particular in disorders characterized 
by both structural and metabolic defects. Moreover, even if the rod localization is 
often cytoplasmic, intranuclear rods have been found in some patients.  
Recently, Vanderbrouck et al.[
85
] investigated rod formation associated with 
structural disorganization of the thin filament transfecting cells with several 
constructs carrying ACTA1 mutations reported in NM patients, and compared that 
with the rod formation induced by ATP depletion. In this study it was demonstrated 
that not all rods are formed in the same way and have different protein composition 
and conformation. However, these differences are not dependent on the different 
origin from structural or metabolic defects. 
Skeletal actin was observed in all the rods, but actin dynamics, binding partners, 
and conformation were different under different pathological conditions and in 
relation to rod localization. In intranuclear rods, actin was monomeric and not 
bound to -actinin while -actinin is one of the major constituents of cytoplasmic 
rods in human NM [
86
, 
87
, 
88
, 
89
,
90
]. It is possible that -actinin-actin cross-linking 
occurs later in rod formation when rods are localized to the cytoplasm. This in vitro 
observation is well supported by a report regarding a patient with an ACTA1 
mutation that was biopsied at 7 weeks and then again at 15 months of age [
91
]. In 
this case the rods were reported to be "vague cytoplasmic bodies" at the earlier 
time point, while at the later time point the rods demonstrated a typical "cross-
hatched" or "grid-like" structure. Differences in rod appearance in biopsies from the 
same patient at different time points have been shown to be caused by -actinin-
actin cross-linking that doesn‟t occur in the beginning of rod formation. Moreover, 
Vanderbrouck et al. showed a different expression of cofilin in nuclear and 
cytoplasmic rods. As discussed above, cofilin is involved in actin depolymerization 
and enhances the dissociation of ADP-actin monomers from the growing-end of F-
actin. Mutations in the cofilin gene result in a form of NM and independent from the 
underlying structural or metabolic abnormalities, cofilin has been observed in 
cytoplasmic, but not intranuclear rods. 
Actin turnover is influenced by the site of the mutation, the anatomical localization 
of rods, and the cellular ATP levels [
85
]. These different actin dynamics influence 
the time course of rod formation as well as actin turnover in the sarcomere. This 
leads to structural and functional deficits in muscles associated with muscle 
weakness, such as myofibrillar disruption observed in nemaline myopathy and 
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alterations in the interaction between actin and tropomyosin seen in congenital 
fiber-type disproportion. 
In conclusion, rods derived from the presence of actin mutations and ATP depletion 
show similar features, suggesting that both, structural and metabolic defects 
contribute to rod formation and composition. However, the mechanisms of rod 
formation in these conditions need to be investigated in order to shed light on their 
function in NM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Nemaline rods in NM patient - Electron micrograph. An area of relatively 
normal muscle structure (small arrows, bottom right) is seen next to a structurally 
disorganized region with multiple nemaline rods (large arrows) and disorganized 
thin filaments (top left). (Sanoudou and Beggs, trends in Molecular Medicine, 2001) 
 
1.2.3 Genetics of Nemaline Myopathy 
1.2.3.1 Causative genes  
NM is heterogeneous also from a genetic point of view. Causative mutations 
leading to NM disease can occur in Acta1 (skeletal muscle -actin), Neb (nebulin), 
Tpm3 (slow alpha-tropomyosin; alpha-3 chain), Tpm2 (beta tropomyosin), Tnnt1 
(slow troponin T), and Cfl2 (cofilin 2). All these genes encode thin filament proteins. 
This huge heterogeneity in terms of inheritance and causative genes makes the 
genetic test for NM complex. Based on the literature, about half of NM cases result 
from Neb mutations. Neb genetic testing is available but is expensive because of 
the large size of the gene. Acta1 mutations are responsible for 20-25% of all NM, 
while mutations in the other causative genes are responsible for the remaining 30% 
of NM cases. This distribution among NM patients reflects the important role of 
nebulin in the sarcomere due to its giant size (isoforms from 600 to 800 kDa). In 
fact, when a mutation occurs in Neb, it seriously affects thin filament stability. Since 
over 20 years ago nebulin was considered a “molecular ruler”, specifying actin 
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filament length. However, due to its large size and susceptibility to proteolysis, it 
has been always hard to work with nebulin and directly demonstrate its role in 
specification of thin filament length. In a nebulin knockout developed by Bang et al, 
shorter, but uniform thin filaments were observed [
25
], in contrast to the expected 
lack of the thin filament regulation. This suggested that a nebulin-independent 
mechanism controls immature actin filament length, while nebulin is responsible for 
specifying filament mature length. Apparently in contrast to Bang et al., a study on 
another nebulin knockout mouse reported the presence of shorter non-uniform thin 
filaments. However, while in the first study the mice were analyzed at 1 day after 
birth, the second study was carried on 10-15 days old mice. This could provide the 
basis for the discrepancy, suggesting that the actin filament length non-uniformity 
arise from muscle use over time.  
More recently, studies have definitely shown that nebulin is not a molecular ruler of 
thin filaments: i.e. when nebulin was replaced with a constructed “mini-nebulin” in 
skeletal muscle cells, actin filament assembly was not restricted to the size of mini-
nebulin. Taken together these findings reveal that nebulin regulates thin filament 
length by stabilizing the filament and preventing depolymerization, but not by a 
traditional ruler mechanism.  
In addition, it has been reported that while nebulin‟s C-terminus bind and colocalize 
with the barbed-end actin binding protein, CapZ, its N-terminus does not colocalize 
with the pointed end capping protein tropomodulin (Tmod) as previously thought. 
How nebulin interacts with CapZ is not clear, since the precise layout that nebulin 
adopts in the Z-disc is unknown. One of the most recent hypothesis is that a 
significant amount of nebulin is placed in the Z-disc where it crosses from one thin 
filament to the next, connecting adjacent sarcomeres. It has been also supposed 
that nebulin stabilizes actin filaments, either directly by providing actin monomers 
with additional molecular contacts and preventing their dissociation from the 
filament, and/or indirectly by stabilizing tropomyosin, which prevents actin 
depolymerization (see paragraph 1.1.2). Finally, a last hypothesis is that nebulin 
stabilizes the thin filament by exerting a compressive force as suggested by the 
evidence that nebulin is quite compliant, and when fully extended may apply a 
significant restorative force to the thin filament. This force could prevent actin 
depolymeriazation by protecting the thin filament.  
In the last years nebulin has shown to exhibit additional other functions, such as 
specifation of Z-disc structure and width as well as proper contractile function of 
skeletal muscle. 
1.2.3.2 Genetic pathways underlying NM 
Owing to the genetic heterogeneity of NM, Sanaoudou et al. investigated the gene 
expression profile of NM patients with the intent to shed light onto the genetic 
defects at the basis of the disease. In this study, muscle specimens from patients 
of all ages, disease states, and genders, were used to minimize the bias introduced 
by each of these factors. Deregulated genes were found in different pathways, 
such as glucose/glycogen metabolism-related, fatty acid metabolism, cell cycle 
control, transcription/translation-related, ubiquitin-related, muscle and nerve, Ca
2+
 
homeostasis, and signal transduction. 
The most interesting changes are reported in the paragraphs below. 
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- 1.2.3.2.1 Changes in satellite cells: indication of regenerative response in NM 
muscles? 
An increase in satellite cell number was found in myofibers from NM patients and 
was confirmed by the overexpression of NCAM1 and CDK4, two genes expressed 
in myoblasts. However the expression level of Pax7, MyoD1, Myf5, desmin, 
GLUT1, GLUT4, BCL2, MET, α-7 integrin, and M-cadherin was unchanged. This 
was unexpected since the immunofluorescence study showed an increased 
number of NCAM1 and CDK4 mononucleate cells in NM muscles. Sanoudou et al. 
hypothesized that the relatively unchanged expression of satellite muscle cell 
markers could be due to a dilution effect as satellite cells make up only a few 
percent of total myonuclei [
95
]. Moreover CDK4 overexpression went together with 
downregulation of CUL1, RBL2, and BCL6, three inhibitors of the cyclin D2/CDK4 
pathway, the pathway promoting the progression from G1 to S-phase. At the same 
time, FIBP, a mitogenesis-promoter gene was overexpressed too. The possibility 
that other cells, such as fibroblasts, could account for this alteration does not seem 
reasonable. In fact, fibroblast proliferation and increased fibrosis are not detected 
in NM skeletal muscle patients and Duchenne muscular dystrophy muscles, for 
which fibrosis is a prominent feature [
97
], do not present these genetic alterations.  
However, TGFB2, a potent inhibitor of skeletal muscle differentiation [
98
], was 
upregulated, while some inhibitors of the myogenin/MyoD pathways (CARM1, 
MADH3, and NFATC3) were downregulated [
99
, 
100
, 
101
]. In other words, while 
proliferation seems to be promoted, differentiation is inhibited. Thus the increased 
number of satellite cells, in the context of several other changes in expression of 
cell cycle and transcription factors, suggests the possible existence of an abort of 
the regenerative response in NM muscles. 
- 1.2.3.2.2 Altered metabolism in NM muscle 
The altered expression of several genes directly or indirectly involved in the 
glycolytic pathway was revealed in NM muscles. Genes usually expressed at high 
levels in skeletal muscle were under-expressed in NM muscles, such as 6-
Phosphofructo-2-kinase/fructose-2,6-biphosphatase1 (PFKFB1), fructose-1,6-
bisphosphatase (FBP2), phosphoglucomutase (PGM1), and phosphofructokinase 
(PFKM). 
Other metabolic changes were reported in the gene expression analysis, which 
seemed related to the switch from fast to slow fiber type. In fact, the cardiac/slow 
(type 1 fiber) isoform of lactate dehydrogenase (LDHB) was upregulated, even 
though LDHA, the predominant skeletal muscle fast isoform, was unchanged.  
At the same time key enzymes for glycogen metabolism and pathway regulators 
were found to be downregulated. It is well known that NM muscles are enriched in 
glycogen stores [
83
], but the molecular origin of this phenomenon has remained 
unknown. Based on the gene expression studies by Sanoudou et al., the gene 
changes show a reduced reliance on glycolytic energy production above and 
beyond that expected from a shift from fast to slow fiber types in many NM 
patients. This could be the reason for the increased number of glycogen deposits 
in NM muscles. Moreover, several glycolytic enzymes (i.e. phosphofructokinase 
(PFK) and lactate dehydrogenase) bind actin. 
It is known that fatty acid oxidation is increased in NM (because of an increase in 
type I fibers), and as expected the related genes were found altered in the gene 
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expression study, such as PPARD, PPARalpha, PPARgamma, and RXRA, 
promoting fatty acid oxidation. 
The most downregulated gene in NM was the uncoupling protein 3 (UCP3) (range 
5.1- to 12.6-fold for three probe sets), while UCP3 protein was found to be 
increased by immunoblotting. This observation suggests the existence of a 
negative feedback loop where increased protein levels downregulate UCP3 gene 
expression. An inverse relation between mRNA and protein levels for UCP3 has 
been reported, i.e. in normal muscle this protein is the most abundant in human 
fast type 2B fibers [
106
], whereas mRNA expression is directly correlated with 
percentage of slow type 1 fibers [
107
]. In NM muscles, UCP3 regulation appears 
reversed, with mRNA levels indicating an increase in slow type I fibers, while there 
is no clear correlation between fiber type proportions and UCP3 protein levels. 
UCP3 has been reported to be involved in the regulation of mitochondrial fatty acid 
transport and glucose metabolism in skeletal muscle, protection against excessive 
production of reactive oxygen species, and regulation of whole-body energy 
metabolism [
108
]. Thus, the increase in UCP3 protein levels and the subsequent 
enhancement of fatty acid oxidation is consistent with the shift from the glycolytic to 
oxidative pathway of energy production, from fast fibers to slow fibers. 
- 1.2.3.2.3 Alterations in Ca
2+ 
 pathways 
The gene expression study revealed an aberrant expression pattern of genes 
involved in calcium (Ca
2+
) homeostasis, such as ATP2A1, ANX7, CASQ2, DMPK, 
and HSBP2 that are responsible for the translocation of Ca
2+
 from the cytoplasm to 
the sarcomplasmic reticulum (SR) [
109
,
110
,
111
], suggesting an overall increase in 
cytosolic Ca
2+
. The increase in cytosolic Ca
2+ 
could be also explained by the 
reported changes (FADS1, PAFAH1B1, and CYP2J2 genes) in the arachidonic 
acid metabolism [
112
]. The increase in cytosolic Ca
2+
 has been correlated to insulin 
resistance [
113
] and the presence of altered genes related to a mild form of insulin 
resistance in NM patients has been identified in the gene expression study. For 
example, hexokinase and insulin receptor substrate (IRS1), two proteins with 
potentially significant roles in insulin resistance, are downregulated [
118
]. 
The gene expression study also revealed a downregulation of calcium-regulated 
signaling molecules that might be caused by a negative-feedback loop where the 
chronic increased cytoplasmic Ca
2+
 level leads to a compensatory reduction in 
transcription of corresponding genes, similar to observations in muscular 
dystrophies [
119
, 
120
]. Moreover, changes in Ca
2+
 homeostasis could affect 
sarcomere structure and muscle contraction. 
1.2.4 Mouse models of NM 
- Several mouse models of NM exist with varying degree of disease severity. In this 
study we took advantages of three mouse models: a nebulin knock-out mouse, an 
ACTA (H40Y) knock-in mouse, and an alpha-Tropomyosinslow(Met9Arg) transgenic 
mouse.  
-  
1.2.4.1 Nebulin knock-out mouse 
The nebulin knockout mouse (NKO) is the one generated by Bang et al. [25]. It 
develops progressive sarcomeric disorganization, misalignment, and Z-line 
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widening reminiscent of NM, resulting in death within 11 days after birth due to 
decreased milk intake and muscle weakness.  
However, although this mouse line develops some features of NM, it is not an 
optimal model for NM since no patients with complete absence of nebulin have 
been described.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 NKO mice 1-day and 8-days old compared with the wt littermates. The NKO 
mice are small and die at 8-11 days after birth (Bang et al, JBC, 2007) 
 
 
1.2.4.2 alpha-Tropomyosinslow(Met9Arg) transgenic mouse 
This model is a mouse line with transgenic expression of the dominant negative 
alpha-Tropomyosinslow(Met9Arg) mutant (human TPM3 gene) in skeletal muscle 
(Tmslow(Met9Arg) Tg; 13), a mutation identified in a childhood form of NM [221]. 
This mouse line develops a mild form of NM but exhibits all features of the human 
disease, including the presence of nemaline rods in skeletal muscle as well as an 
increase in the number of slow/oxidative fibers and late onset muscle weakness 
starting from around 7 months of age.  
Similar to observations in human patients, gene expression profiling on this mouse 
model revealed activation of satellite cells and focal repair processes in multiple 
muscles, a feature that was previously not considered characteristic for NM. On the 
other hand, no signs of metabolic changes were found except for in the most 
affected diaphragm where a number of mitochondrial genes involved in energy 
production were downregulated. This suggests that reduced energy production is a 
secondary effect observed in more severe stages of NM, such as in the diaphragm 
of Tmslow(Met9Arg) Tg mice and the majority of human patients included in the 
gene expression study [217].  
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1.2.4.2 ACTA (H40Y) knock in mouse 
This is a knock-in mouse model expressing a mutant form of -skeletal actin, 
containing a single AA change (H40Y) that causes an early onset dominant form of 
NM [18]. This mouse line exhibits an early onset severe form of the disease and 
displays all the clinical and pathological features of patients with the ACTA1(H40Y) 
mutation, including the presence of both cytoplasmic and nuclear nemaline rods. 
Similar to patients harboring the ACTA(H40Y) mutation, Acta1(H40Y) KI mice 
contained nemaline rods both in the cytoplasm and the nucleus and died early, i.e. 
61% of male and 3% of female Acta1(H40Y) KI mice died by 13 weeks of age. 
Forelimb strength was significantly reduced in KI mice and Acta1(H40Y) KI mice 
had watery eyes and kyptosis (drooping eyelids). Furthermore, Acta1(H40Y) KI 
mice exhibited muscle atrophy and an increased number of slow oxidative fibers. In 
addition, Acta1(H40Y) KI muscle contained areas of myofiber degeneration, 
infiltrating mononucleated cells, and fibers with internal nuclei, indicating ongoing 
chronic repair and regeneration as recently recognized as characteristic features of 
NM [12, 15].  
Besides fiber atrophy, other changes are likely to contribute to the muscle 
dysfunction in Acta1(H40Y) KI mice, such as a reduced twitch force of isolated 
whole muscles, that suggests changes in the quality of contraction. Interestingly, 
ACTA (H40Y)KI mouse muscle has been shown to have a reduced proportion of 
strongly bound myosin cross-bridges during contraction  that well correlate with the 
recent findings in NM patients (Hardeman lab, data not published).  
 
The ACTA (H40Y)KI characteristics are reported in fig.5. 
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1.              2.  
 
3.              4.  
5.                                    6.  
 
Fig.5 Major characteristics of ACTA (H40Y)KI mouse phenotype: 1.Atrophy of 
facial muscles evident in some knock-in mice 2. Increased mortality 3. Marked 
decrease in forearm grip strength 4. Decrease in force 5. Cytoplasmic (5A) and 
nuclear (5B) rods 6. Evidence of myofiber repair/regeneration 
(Hardeman lab, data not published) 
1.3 microRNAs 
1.3.1 miR biogenesis 
MiRs (miRs) are a class of small RNAs, usually 20-24 nucleotides long, that 
function as post-transcriptional regulators of gene expression [
122
]. The pathways in 
which miRNAs are involved are numerous, including cell proliferation, 
differentiation, apoptosis, and development [
123
, 
124
, 
125
]. As they regulate the 
expression of fundamental physiological processes, their deregulation leads to 
many disorders, such as cancer [
126
, 
127
, 
128
] and neuromuscular disorders [
129
, 
130
]. 
Most miRs are located in introns of protein-coding genes and in intergenic regions 
and their transcription is operated by RNA polymerase II (Pol II) [
131
, 
132
], except for 
some that are transcribed by RNA polymerase III (Pol III) [
133
]. However, miR 
biogenesis is a long process, where the transcribed sequence is subsequently 
modified by endonucleolytic proteins.  
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The primary miR (pri-miRNA) is capped and polyadenylated and is a long hairpin 
structure with unique features that distinguish it from the various RNA stem-loop-
like structures present in the nucleus. In particular, a long imperfect stem of 
approximately 30 bp is flanked by single-stranded RNA segments at its base [
134
, 
135
]. This peculiar structure is recognized by the Microprocessor complex, that 
contains Drosha (RNase III enzyme), the RNA binding protein DGCR8 [
136
, 
137
, 
138
] 
and other proteins [
139
, 
140
]. The region of the pri-miRNA, containing the junction 
single-stranded RNA–dsRNA, is identified by DGCR8 [
135
], and Drosha operates 
the first cut at a distance of approximately 11 bp from the junction. This process 
occurs co-transcriptionally, before the splicing of the host RNA [
141
, 
142
].  
As all RNAse III products, the resulted structure, called precursor miR (pre-miR) 
has 2 nucleotides protruding at the 3‟ end [
143
]. It is a long truncated harpin formed 
by 60 nt with a minimal double-stranded stem length of 16 bp [
144
]. These structural 
elements are essential for the recognition by Exportin-5 (Exp-5) [
145
, 
146
]. This is the 
protein that in cooperation with the guanine triphosphatase (GTPase) Ran 
transports the pre-miRNA from the nucleus to the cytoplasm, allowing it to be 
recruited by Dicer (another RNase III enzyme), maybe passing it directly to Dicer or 
via additional components [
147
]. The 3‟-ends generated by Drosha are recognized 
by Dicer that cleaves the pre-miRNA near the terminal loop, generating a miRNA–
miRNA* duplex having 2-nt 3‟ overhangs at both ends [
148
, 
149
]. 
Human Dicer is a multidomain protein of approximately 200 kD. The N-terminal 
DEAD-box helicase domain, a domain of unknown function (DUF283), a PAZ 
domain, two conserved catalytic RNase III domains (RIIIA and RIIIB) and a C-
terminal dsRNAbinding domain (dsRBD) are contained in this protein [
150
]. RIIIB 
and RIIIA cut the 5‟ and 3‟ arms of the pre-miR, respectively [
151
, 
152
]. Different 
members of the RISC loading complex (RLC) cooperate with Dicer during its 
function [
153
, 
154
]. Among them there are members of the argonaute (AGO) family 
[
155
, 
156
], HIV-1 transactivation response (TAR), RNA-binding protein (TRBP) [
157
, 
158
], and possibly other proteins. The miRNA strand (guide strand) of the duplex 
resulting from Dicer cleavage of the pre-miRNA is loaded onto AGO to form the 
RNA-induced silencing complex (RISC or mi-RISC) and the released other strand 
(passenger strand or miRNA*) is degreaded [
157
, 
159
, 
160
]. The strand selection is a 
crucial step of the miR biogenesis; it has suggested that thermodynamic stability of 
the ends of the miRNA duplexes [
161
, 
162
], structural features of the miRNA/miRNA* 
duplex (e.g. positions of base mismatches) [
163
, 
164
, 
165
], and sequence composition 
[
166
, 
167
] are the factors contributing to strand selection. However cases where both 
miRNA and miRNA* strands may be involved in RISC-mediated gene silencing 
have been reported [
165
, 
168
]. 
The miR biogenesis illustrated until now is the canonical pathway, but „„non-
canonical‟‟ pathways of miRNA biogenesis exist too [
169
]. One of the most common 
is involving sequences spliced out of mRNA transcripts that are pre-miRNA-like 
introns called mirtrons [
170
, 
171
, 
172
]. As they are already pre-miR-like sequences, 
they bypass the Drosha requirements, following the canonical pathway [
173
]. In fig.6 
are shown all the known canonical and non-canonical miR biogenesis pathways 
[
174
, 
175
, 
176
]. 
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Fig.6 Canonical and non canonical pathways of microRNA biogenesis  
(Miyoshi et al, Molecular Genetics Geomics, 2010) 
 
 
1.3.2 miRNA-mRNA interaction 
A central goal for understanding miR functions has been to understand how they 
recognize their target message. The 5‟ region of the miR called the SEED 
sequence is important for target recognition with nucleotides from 2 to 7 that pairs 
with the 3‟UTR of the mRNA target [
177
, 
178
, 
179
]. The region of mRNA pairing with 
the SEED sequence has been conserved in one-third of human genes [
180
].  
There are four different types of sites associated with messages downregulated by 
miRNAs. This includes one 6mer, two 7mers, and one 8mer (fig.7). 
The 6mer is the perfect 6 nt match to the miRNA seed (miRNA nucleotides 2–7) 
[
180
]. The best association is the 7mer site, in which the seed match is augmented 
by a match to miRNA nucleotide 8 [
177
, 
178
, 
179
]. The seed match augmented by an 
A at target position 1 is typical of the 7mer-A1 site, while in the 8mer site the seed 
match is flanked by both the match at position 8 and the A at position 1 [
180
]. 
Not perfect matches in the SEED sequence have also been observed in functional 
miRs. 
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Fig.7 Canonical miRNA complementary sites (Grimson et al, Molecular Cell, 2007) 
 
However, seed sites do not always confer repression, and when repression occurs, 
the degree of repression is highly variable in different UTR contexts. Interestingly, 
in a tissue in which a miR is highly expressed, messenger RNAs of genes 
encoding proteins with an important role in the tissue have 3‟UTRs that are 
depleted in 7mer sites, presumably to avoid acquiring sites for the co-expressed 
miRNAs that would compromise their function [
181
]. 
The mechanism of specificity can be explained at least partly in terms of site 
accessibility and site affinity, which influence the association and dissociation of the 
silencing complex. It has been shown that the context features that help specificity 
miRNA targeting is important [
182
], i.e. there are supplemental pairing outside of the 
seed region, particularly to nucleotides 13–16 of the miRNA, that could decrease 
the dissociation rate of the bound RISC. Moreover the accessibility of the seed site 
on the mRNA could be increased by the presence of weak mRNA secondary 
structure, conferred by the presence of AU enrichment in the region immediately 
flanking the SEED region. 
It is well known that miRs can have multiple targets, and multiple sites on the same 
mRNA target. This allows one miR to regulate the gene expression of hundreds of 
targets. In the same way, one target can be regulated by more than one miR. The 
possibility that two or more sites for one or more miRs on a mRNA target lead to a 
cooperative regulation of gene expression has been investigated. It has been 
observed that multiple sites for the same miR cooperate in increasing repression, 
while the overlapping or near-overlapping sites for two different miRNAs cause less 
21 
 
downregulation than more distantly spaced sites, possibly due to cooperative 
contacts with the repressive machinery [
182
]. 
Recently, a new class of miR targets containing simultaneous 5‟UTR and 3‟UTR 
interaction sites has been identified [
183
]. Of these, many miRNAs with their 3'-end 
interaction sites in the 5'-UTRs turn out to simultaneously contain 5'-end interaction 
sites in the 3'-UTRs, leading to a combinatory interactions between a single miRNA 
and both end regions of an mRNA.  
1.3.3 microRNAs-mediated gene expression regulation 
It is known that miRs can inhibit gene expression by affecting protein synthesis or 
by destabilizing mRNA structure, leading to its degradation. The regulation at the 
translational level is the most common. However, whether it occurs at the initiation 
or post-initiation step (or both) is not yet well understood. In the next paragraphs 
the most recent models of gene expression regulation by miRs are discussed 
(fig.9). 
1.3.4. Models of translational repression 
1.3.4.1 Repression at the initiation step 
During initiation of transcription the presence of several initiation factors (eIF) and 
in particular the ability of one of them (eIF4G) to interact simultaneously with eIF4E 
(bound to the mRNA 5‟UTR) and PABP1 (bound to the mRNA 3‟UTR), brings the 
two ends of the mRNA in close proximity [
184
, 
185
].  
The presence of a limited sequence homology between AGO proteins and the cap-
binding region of eIF4E [
186
] has recently been reported. Even if limited, the 
similarity includes two aromatic residues crucial for the cap binding of eIF4E [
186
], 
suggesting the possibility of competition between AGO2 protein and eIF4E for cap 
binding, thus preventing translation initiation. The RISC complex is directed to the 
3‟UTR thanks to the miR interaction with the seed site of the target, and the 
circularization of the mRNA allows AGO2 protein interaction with the cap-binding 
site protein. Moreover, the requirement for multiple miRNPs or tethered AGO 
molecules for robust repression could be necessary to increase the likelihood of 
AGO association with the cap [
187
, 
188
, 
189
, 
190
]. 
 
1.3.4.2 Repression by preventing 60S subunit joining  
One model of translational initiation repression by miRs comes from the 
observation that eiF6 and 60S ribosomal subunits co-immunoprecipitate with the 
RISC complex [
191
]. eiF6 is involved in the biogenesis of the 60S subunit in the 
nucleolus and is associated to the this subunit in the cytoplasm [
192
, 
193
,
194
]. It is 
supposed that the RISC complex interacts with the eiF6 factor, promoting the 
repression of the transcription by the impediment of the 60S joining to the 
translational machinery. This is supported by the evidence that partial depletion of 
eIF6 rescues mRNA targets from miRNA inhibition [
191
] 
1.3.4.3 Repression at post-initiation steps  
In the last years several studies have shown that mRNA repression through miRs 
is not occurring only at the translation inititation step. The mRNA targets, together 
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with miRNAs and AGO proteins, have been found associated with polysomes, 
suggesting that gene expression repression is possible after the initiation of 
translation [
195
, 
196
, 
197
]. It has to be considered that not only one miR-directed RISC 
complex bound to the mRNA is able to repress gene expression alone. Thus, it is 
possible that the miRISC-mRNA found to be associated with polysomes reflect the 
failed translation repression, and thus a productive translation [
189
, 
190
]. 
However, a model of post-initiation repression has been suggested by Peterson et 
al [
198
], that proposed a drop-off model, in which miRs induce the drop off of the 
ribosome and the consequent premature termination of translation. The post-
initiation repression has been reported in IRES-containing targets, where the 
translation is not started in the conventional way, but with the entry of the ribosome 
directly on the IRES (Internal Ribosome Entry Sites) [
199
].  
The mechanism for the modulation of elongation or termination processes through 
miRs has not yet been elucidated. However, it has been hypothesized that initiation 
and post-initiation repression can occur together; it is possible that initiation is 
always inhibited and that the simultaneous repression of the elongation step 
causes the presence of more ribosomes stopped on the mRNA [
122
]. 
1.3.4.4 mRNA deadenylation and decay 
Recently studies have shown that gene expression repression of miRNAs targets is 
sometimes associated with their destabilization, revealed by low levels of mRNA 
[
200
, 
201
, 
202
]. mRNA degradation can be achieved through two different pathways, 
both of them starting with mRNA poly(A) tail shortening. After that or degradation of  
mRNA by 3′→5′ decay, catalysed by the exosome, or by 5′→3′ degradation after 
removing of the cap, catalysed by the exonuclease XRN1, can occur [
203
]. The 
mRNA under degradation are moved to the P-bodies, cellular structures that are 
enriched in mRNA-catabolizing enzymes and translational repressors [
204
, 
205
]. It is 
evident that the association with AGO instead of eIF4E leads to a disruption of 
mRNA structure, making it more vulnerable to degradation, but it is not clear 
whether the degradation is always secondary to translational repression.  
Recently it has been demonstrated that under certain conditions, or in specific 
cells, the miRNA-mediated repression can be reversed or prevented [
206
, 
207
, 
208
, 
209
]. The possibility and the ability of mi-RISC complexes to be removed from the 
target mRNA confer a much more dynamic regulation function to the miRs.  
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Fig.8 microRNAs mediate gene expression through multiple mechanisms: (a) 
microRNAs could repress translationally competent ribosomes after initiation, either 
promoting ribosome drop off during elongation or cotranslational degradation of the 
nascent polypeptide, (b) microRNAs promote deadenylation and degradation of 
their targets.(c) microRNAs block translation initiation through competition for the 
cap structure between microRNP and EIF4E 
(Maroney et al, Nature Structural and Molecular Biology, 2006) 
 
1.3.5 miRs in serum 
One of the most recently discoveries regarding miRs is their ability to circulate in 
serum, remaining stable. In a recent study circulating miRs have been subjected to 
severe conditios, such as boiling, very low or high pH, extended storage, and 10 
freeze-thaw cycles, in which they have been shown to be stable [
210
]. As well as 
their stability under these hard conditions, they are protected in the serum from 
RNAse activity [
211
, 
212
], and the mechanism at the basis of this protection has been 
object of several recent studies.  
It is thought that inclusion in lipid or lipoprotein complexes protects the circulating 
miRs from RNAse digestion [
213
]. Moreover it has been reported that miRs are 
exchanged between cells, going out from one donor cell, circulating in the 
intracellular space, and being included in the recipient cell. During this exchange 
miRs are protected either in microvescicles (up to 1 μm) or in small membrane 
vesicles of endocytic origin called exosomes (50 – 90 nm) [
214
, 
215
]. The miRs are 
included in the multivesicular bodies (MVB) in their precursor form (pre-miRNA) 
and then associated with exosomes. The MVBs fuse with the plasma membrane, 
releasing the exosomes in the circulating compartments and bloodstream. When 
the exosomes contact the recipient cell, the miRs are donated to that cell by 
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endocytosis. At this point the pre-miR is processed by DICER and loaded into the 
RISC complex as an endogenous miR. However it remains to be elucidated if pre-
miRNAs or mature miRNAs are involved in this process [
216
]. 
It has been reported in the literature that altered levels of miRs in the serum can be 
related to pathologies such as cancer and hypertrophy, and can be used as 
biomarkers [
217
, 
218
]. 
1.3.6 Target prediction algortihms 
In the past years several bioinformatic tools for miR target prediction have been 
developed, based on the rules for miRNA-mRNA interaction reported in the 
literature. Here the most commonly used target prediction tools available in the 
web are described. 
The miRanda target prediction algorithm [
219
, 
220
] predicts targets adopting a three 
steps procedure: first miR recognition elements (MREs) for the miR of interest are 
searched among the mRNA sequence; then the free energy of the putative pairing 
is calculated, and in the end the predicted targets are filtered by evolutionary 
conservation. The definition of cutoff parameters for the algorithm is subjected to 
heuristics, which follow the incremental knowledge about the experimentally 
verified MREs. 
The TargetScan algorithm [
221
] is mainly based on the hypothesis that highly 
conserved miRNAs are more involved in regulation and that membership in large 
miRNA families lead to more targets. As a consequence it includes in input 
sequences the miRNA mature sequences as well as a set of orthologous 3'-UTR 
sequences conserved in multiple organisms. This algorithm is based on a different 
three steps procedure than miRanda. First perfect Watson-Crick complementarity 
along the SEED sequence is required; then it extends the seed matches in both 
directions, allowing wobble pairs and stopping at the first mismatch encountered. In 
the end the algorithm explores the remaining 3' region of miRNA and spreads 
sequence matching for the 35 nucleotide away from the seed. A thermodynamical 
evaluation is performed on the miRNA-mRNA duplex. The entire process is for 
performed for each of the organisms, belonging to the UTR dataset. In this way the 
conserved miRNA target pairs are taken into account.  
RNAhybrid [
222
] is based on the prediction of RNA secondary structure, exploring 
the conformational space of all possible secondary structures established between 
the miRNA and target sequences. A statistical analysis of thermodynamical 
evaluation is carried on the predicted interactions. The most favorable structures 
are referred to as minimum free energies (MFEs) and are scored by the p-value.  
PITA [
223
] stands for Probability of Interaction by Target Accessibility. This target 
prediction method is based on the evaluation of MRE site accessibility based on 
thermodynamics. Moreover the interaction score is weighted by also taking into 
account the steric hindrance of the entire ribonucleoprotein complex. 
1.3.7 microRNAs in Nemaline Myopathy 
In a recent study, a large number of miRs were shown to be dysregulated in 10 
major congenital muscle disorders, including NM, suggesting that miRs may play 
important roles in the regulation of pathological pathways leading to muscle 
dysfunction [
224
]. Interestingly, while some miRs were dysregulated in all the 
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studied muscle disorders, suggesting their involvement in common regulatory or 
compensatory mechanisms, others were dysregulated only in a specific disease. In 
particular NM patients were characterized by a miR expression profile distinct from 
that of any of the other muscle disorders, possibly reflecting the fundamental 
difference between NM and other neuromuscular diseases. Thus, more than 150 
miRs were dysregulated in NM, more than in any of the other studied disorders, 
and 36 miRs were specific to NM, suggesting the existence of unique regulatory 
mechanisms modulated by miRs underlying the pathology of NM. In NM, as in all 
the studied muscle disorders, the vast majority of dysregulated miRs (140 of the 
153) were upregulated; 7 of the upregulated miRs (hsa-miR-125a, hsa-miR-128a, 
hsa-miR-128b, ambi-miR-4983, hsa-miR-28, hsa-miR-362, hsa-miR-542-5p) were 
identified as class predictor of the NM compared to normal muscle, with 100% of 
accurancy.  
Target prediction analysis was carried out in the study and to analyze the role that 
the differentially expressed miRNAs play in the regulatory networks in muscular 
disorders, Eisenberg et al. used the KEGG database and the DAVID bioinformatics 
resources [
225
]. In this way they identified significantly overrepresented biological 
pathways among the miR predicted targets.  
In NM, the pathways more enriched by predicted targets of dysregulated miRs 
were the focal adhesion pathway (involved in cell communication), the calcium 
signaling and TGF beta signaling pathways, as well as the regulation of actin 
cytoskeleton. Enrichment in the MAPK signaling pathway, the T cell receptor 
signaling pathway, tight junction, ECM receptor interactions, and inositol phosphate 
metabolism was also shown, but with a lower significance.  
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2.RESULTS 
2.1 Difficulties in the beginning of the project 
The aim of the project was to study the role of microRNA (miR)-regulated pathways 
underlying Nemaline Myopathy (NM) based on the use of mouse models with 
mutations directly mimicking human NM-causing mutations. The first step was to 
investigate the miR expression profile.  
 
Initially, the idea was to have a complete overview on dysregulated miRs in the 
mouse models to further compare them with the miRs already found to be 
dysregulated in NM patients [212]. An alternative approach could be to select the 
most changed miRs from the human patient study and investigate their expression 
in our mouse models. However, we hypothesized that also other miRs may be 
dysregulated that may have been missed in the human study because of the 
heterogeneity of the human samples. For this reason we found it useful to study 
the miR expression profile in a cleaner system such as a mouse model.     
 
The first mouse model that we had the possibility to work on was the nebulin 
knockout (NKO) mouse, developed by Bang at al. [25]. Although no patients with 
complete absence of nebulin have been described, these mice develop 
progressive sarcomeric disorganization, misalignment, and Z-line widening 
reminiscent of NM, resulting in death within 1-2 weeks after birth due to decreased 
milk intake and muscle weakness. For a pilot study, we selected three miRs  
(miR128, miR-181, and miR-196a), which were highly and uniquely expressed in 
human NM patients. By quantitative realtime PCR (qRT-PCR) (QuantimiR kit – 
SBI) we confirmed their overexpression also in the diaphragm and tibialis anterior 
of NKO mice compared to wildtype (WT) (data not shown). Based on this result we 
went on to investigate the whole miR expression profile in diaphragm and tibialis 
anterior from NKO mice compared to WT using the Illumina miR microarray 
platform, which was supposed to be robust and cost effective. However, 
unfortunately the scanned chips showed errors not related to sample quality but to 
the chips themselves and although we repeated the miR microarray experiment 
twice, we got no useful results. For that reason we decided to move to another 
system for analysis of the miR expression profile and the Illumina chips have 
subsequently gone out of production 
 
At that time we had the opportunity to start a collaboration with Prof. Hardeman, 
who provided us with two mouse models: the Tmslow(Met9Arg) Tg and the 
ACTA1(H40Y)KI mice that better recapitulate the NM patient characteristics than  
the NKO mouse line. In particular, the Tmslow(Met9Arg) Tg mouse shows the 
mildest phenotype, with onset of the disease at 8 months of age, while the 
ACTA1(H40Y)KI mice have a severe form of the disease, resulting in death of 
males around 10 weeks of age. Intriguingly, ACTA1(H40Y)KI females are less 
severely affected than the males and are able to breed.   
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Using the quantimiR profiling System (System Bioscience) we investigated the miR 
expression profile in diaphragm and tibialis anterior muscle from 3- and 10-week-
old ACTA1(H40Y)KI mice compared to WT (biological triplicates). This system is 
based on qRT-PCR technology and provides two 384-well plates containing probes 
for all miRs reported in miRBase (database of published miR sequences and 
annotation). This approach turned out to be much more cumbersome than 
expected since for each sample the operator is required to move each probe from 
the stock plate to the sample plate and subsequently add the PCR mix. This is not 
only time consuming but also causes inaccuracies due to pipetting errors given the 
high number of samples as well as the high sensitivity of the real-time PCR 
instrument. Also, no technical replicates were provided so it was difficult to 
evaluate if the results were reliable and the biological replicates often showed 
conflicting results. For that reason we concluded that this was not the optimal 
approach to adopt for our studies.  
 
Finally, owing to these technical problems we decided to carry on the analysis of 
miR expression levels only on miRs pre-selected from the most upregulated miRs 
in NM patients [212].  
2.2 Gene expression microarray study on the ACTA(H40Y)KI 
mouse 
As discussed above (paragraph 1.2.4.2), the ACTA (H40Y)KI (KI) mouse model 
shows gender-related differences in the development of the phenotype, with males 
developing an early onset of the disease, resulting in death at around ten weeks, 
while females show a milder phenotype and survive up till at least a year of age. To 
determine the molecular basis for the development of the disease and the 
difference between males and females, we performed the gene expression study 
on diaphragm (DIA) and tibialis anterior (TA) muscle of WT and KI mice from 3-
week-old males and 10-week-old males and females. The study was performed in 
triplicates and the correlation (expressed in r
2 
value, the closer it is to 1, the better 
the samples correlate) between biological triplicates was analyzed and reported for 
each condition in the following paragraphs. GeneSifter was the software used for 
the analysis. The complete lists of altered genes in each condition with fold ≥ 1.4 
and pvalues <0.05 are reported in Appendix A. 
2.2.1 Gene expression analysis of 3-week-old males 
Biological triplicates of 3-week-old males correlated well with an r
2
 value over 0.9 
for both DIA and TA. The DIA of 3-week-old males showed the highest level of 
gene dysregulation, presenting 493 genes with altered expression with fold 
changes ≥ 1.4 and p-values < 0.05; in particular 421 genes were downregulated 
and 72 were upregulated. In terms of fold change, downregulated genes were most 
changed, with fold changes between 1.5 and 8.1, while upregulated genes showed 
differences ranging from 1.5 to 2.3 fold change. When the fold change cut-off was 
set to 3, 187 genes were found to be downregulated, of which the major part (110) 
were involved in metabolic processes, in particular metabolism, such as protein, 
lipid, and nucleic acid metabolic processes.  
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The most downregulated gene was orosomucoid (Orm) (8.1 fold), also called 
alpha-1 acid glycoprotein, which is an abundant plasma protein that works as 
immune-modulator induced by stress conditions such as infections. The role of 
Orm has been investigated in adipose tissue of obese mice [214] and was shown 
to suppress excess inflammation that otherwise disturbs energy homeostasis. 
Other genes involved in the acute phase response were highly downregulated; in 
particular four members of the serpin family: serpind1 (5.4 fold), serpina10 (6.1 
fold), serpinf2 (6.5 fold), and serpina6 (6.5 fold). Serpins are a group of proteins 
with similar structure, first identified as a set of proteins able to inhibit proteases. 
Serpind1, serpina10, and serpinf2 inhibit thrombin, coagulation factors Xa and Xia, 
and plasmin, respectively. Serpina6 is a non-inhibitory member of the serpin-family 
and is the high-affinity transport protein for glucocorticoids in vertebrate blood, 
playing a crucial role in efficient glucocorticoid action in physiology. As illustrated in 
fig.9 the downregulated serpins are involved in pathways that activate the 
complement system, a proteolytic cascade in blood plasma, and a mediator of 
innate immunity. 
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Fig.9 Complement and coagulation cascade KEGG pathways. In red are 
highlighted genes found dysregulated in DIA of 3-week-old males KI 
 
Serpins are also involved in the coagulation cascade in which plasminogen (PLG), 
kininogen1 (KNG), kininogen2 (KNG2), carboxypeptidase B2 (CPB2), and 
fibrinogen (FG) are involved as well. These genes are also downregulated 5.1, 5.6, 
4.3, 5.8 and 4.6 fold, respectively.  
 
Glycolysis was also impaired in the DIA of 3-week-old males, where the glucose-6-
phosphatase catalytic-subunit (G6PC), and fructose-1,6-bisphosphatase 1 (FBP1), 
a gluconeogenesis regulatory enzyme, that catalyzes the hydrolysis of fructose 1,6-
bisphosphate to fructose 6-phosphate and inorganic phosphate, were 
downregulated (2.4 and 5.3 fold, respectively). 
Among the upregulated genes, the most altered gene was RIP13, also known as 
nuclear receptor corepressor 1 (Ncor1), a transcriptional repressor (2.3 fold).  
 
Muscle specific genes such as tropomyosin 3 (TPM3), dystroglycan (DAG1), and 
myocyte enhancer factor 2 (Mef2C) were also upregulated (1.6, 1.7, and 2.1 fold, 
respectively). 
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In the TA of 3-week-old males the expression of 122 genes were shown to be 
changed with fold changes ≥ 1.4 and p-values < 0.05: 115 upregulated and 7 
downregulated. 
 
The most downregulated genes were selenoprotein P1 (Sepp1), an extracellular 
antioxidant involved in the transport of selenium (1.5 fold), and acetyl-coenzyme A 
acyltransferase 2 (ACAA2), involved in mitochondrial fatty acid metabolism (1.6 
fold). Other mitochondrial genes were upregulated, including methyltransferase 
C20orf7 homolog (2310003L22Rik) (2.0 fold), mitochondrial processing peptidase 
beta (PMPCB) (1.8 fold), NADH dehydrogenase (ubiquinone) (1.7 fold), subunit D 
of the succinate dehydrogenase complex (SDHD) (1.7 fold), apoptosis-inducing 
factor, mitochondrion-associated 1 (AIFM1) (1.7 fold), and mitochondrial ribosomal 
protein L20 (MRPL20) (1.6 fold). 
2.2.2 Gene expression analysis of 10-week-old males 
Biological triplicates of 10-week-old males showed a correlation value over 0.9 in 
TA, while in DIA two samples showed a lower correlation value and were therefore 
removed from the analysis.  
 
In the DIA, 41 genes were dysregulated with fold changes ≥ 1.4 and p-values < 
0.05: 20 were upregulated and 21 downregulated. The most dysregulated genes 
encoded proteins involved in the cell cycle, where G0/G1 switch gene 2 (G0S2) 
and PCI domain containing 2 (PCID2) were downregulated (2.3 and 1.4 fold, 
respectively) and damaged-DNA recognition protein 1 (DRP1) was upregulated 
(1.5 fold). 15.4% of altered genes were involved in cellular process, 10.9% in 
biological regulation, 9.9% in metabolic process, and 9.4% in regulation of 
biological process, as showed in fig.10. 
 
 
 
Fig.10 Genes dysregulated in DIA of 10-week-old males grouped in functional 
categories 
 
31 
 
When we looked more in details which were functional categories affected in 
cellular processes, we found that regulation of cellular processes and cellular 
metabolic processes were the most affected, as illustrated in fig.11. 
 
 
 
 
 
Fig.11 Functional categories affected in cellular processes by genes dysregulated 
in DIA of 10-week-old males 
 
 
In the TA of 10-week-old males, 46 genes were dysregulated with fold changes ≥ 
1.4 and p-values < 0.05: 10 were upregulated and 36 downregulated.  
10.5% of altered genes were involved in cellular processes, 9.7% in biological 
regulation, 9.7% in regulation of biological processes, and 8.5% in metabolic 
processes, as illustrated in fig 12 
 
32 
 
 
 
Fig.12 Genes dysregulated in TA of 10-week-old males grouped in functional 
categories 
 
Of the 10.5% altered genes involved in cellular processes, 13.7% were involved in 
regulation of cellular processes, and when we looked more in details which were 
functional categories included in cellular processes, we found that 12.73% of that 
genes were involved in signaling transduction (fig.13). 
 
 
 
 
Fig.13 Functional categories affected in cellular processes by genes dysregulated 
in TA of 10-week-old males 
 
In particular, 11 genes involved in signaling transduction were downregulated: 
adiponectin (2.0 fold), AXL receptor tyrosine kinase (1.6 fold), bone morphogenetic 
protein 4 (Bmp4) (1.4 fold), adipsin (CFD) (2.1 fold), forkhead box O1 (Foxo1) (1.4 
fold), leptin (Lep) (2.3 fold), Map3k6 (1.5 fold), NF1GRP (1.4 fold), plasminogen 
33 
 
activator (1.4 fold), pleckstrin homology-like domain, family A, member 3 (Phlda3) 
(1.6 fold), splA/ryanodine receptor domain and SOCS box containing 1 (Spsb1) 
(1.4 fold). Three genes involved in signaling were upregulated: calcium and integrin 
binding family member 2 (Cib2) (1.5 fold), cell division cycle 34 homolog (Cdc34) 
(1.4 fold) and protein tyrosine phosphatase, receptor type, E (Ptpre) (1.4 fold).  
2.2.3 Gene expression analysis of 10-week-old females 
Biological triplicates of 10-week-old females showed a correlation value over 0.9 in 
DIA, while in TA two samples showed a lower correlation value and were therefore  
removed from the analysis. 
 
In the DIA, 83 genes were dysregulated with fold changes ≥ 1.4 and p-values < 
0.05: 61 were upregulated and 22 downregulated. Several genes involved in the 
cell cycle had altered expression levels and in particular Csnk2a2 (CK2), Ppp3ca 
(CaN), and Camk2b, which were 1.6, 1.4, and 1.4 fold upregulated, respectively. 
These genes code for proteins involved in the WNT pathway, as illustrated in fig 
14.  
 
 
Fig.14 WNT signaling pathway. In red are highlighted genes altered in DIA of 10-
week-old females KI 
 
 
Many genes involved in cellular metabolic processes showed altered expression, in 
particular genes involved in protein metabolic process (fig 14); of these, 41.3% 
34 
 
were involved in protein modification, i.e CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small phosphatase 1 (Ctdsp1) and cytokine inducible 
SH2-containing protein (Cish) were 1.9 and 1.8 fold downregulated, respectively, 
while DnaJ (Hsp40) homolog, subfamily B, member 2 (Dnajb2) and dual specificity 
phosphatase 1 (Dusp1) were both upregulated 1.69 and 1.52 fold respectively.  
 
Fig.15 Functional categories affected in protein metabolic processes by genes 
dysregulated in TA of 10-week-old females 
 
In the TA of 10-week-old females, 102 genes were dysregulated with fold changes 
≥1.4 and p-values < 0.05: 51 were upregulated and 51 downregulated. 
Hbb-b1, the beta adult minor chain hemoglobin gene, was the most downregulated 
gene (5.1 fold), and Hba-a1, the alpha adult chain 1 hemoglobin gene was also 
downregulated (2.0 fold). Moreover, Hspd1, which is involved in inflammation, was 
downregulated (2.0 fold). 
2.2.4 Comparison between different conditions and human patients 
As illustrated in fig16-17. there were not so many genes commonly dysregulated in 
DIA and TA in different conditions. Only in 3-week-old males there were two genes 
commonly dysregulated in DIA and TA (fig.16): selenoprotein P,plasma 1 (SEPP1) 
was downregulated 1.54 fold down in TA and 2.97 down in DIA, while N-
acetyltransferase 5 (Nat2) was upregulated 1.59 fold in TA  1.47 fold in DIA. 
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Fig.16 Intersection of dysregulated genes in DIA and TA of 3-week-old males 
 
In 10-week-old males and females there were not genes commonly dysregulated 
between DIA and TA. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.17 Intersection of dysregulated genes in DIA and TA of 10-week-old males and 
females 
 
When we looked for genes commonly dysregulated in DIA and in TA between 3-
week-old males and 10-week-old males and females, there were no genes that 
were common to all the three different conditions (fig18-19). 
 
In fig18 is illustrated the Venn diagram for genes dysregulated in DIA in 3-week-old 
males and 10-week-old males and females  
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Fig.18 Intersection of dysregulated genes in DIA of 3-week-old males and  
10-week-old males and females 
 
 
In DIA the only commonly downregulated gene between 3- (1.4 fold) and 10-week-
old (1.7 fold) males was complement component 2 (within H-2S) (C2). Also, only 
one dysregulated gene was common between 10-week-old males and females; 
serine/arginine-rich protein specific kinase 3 (Srpk3), that was upregulated 1.6 fold 
in males and 1.5 fold in females. On the other hand, 10 genes were commonly 
dysregulated in 3-week-old males and 10-week-old females, which are shown in 
table 1.  
 
Table 1 - Genes commonly dysregulated in DIA of 3-week-old males and 10-week-
old females 
 
 
In fig.19 is illustrated the Venn diagram for genes dysregulated in TA in 3-week-old 
males and 10-week-old males and females  
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19 Intersection of dysregulated genes in TA of 3-week-old males and  
10-week-old males and females 
 
In the TA, no genes were commonly dysregulated between 3- and 10-week-old 
males, while one gene, leucine-rich repeats and transmembrane domains 1 (Lrtm1) 
was commonly downregulated in 10-week-old females (2.30 fold) and 10-week-old 
males (1.60 fold). Again the most commonly dysregulated genes were found in 3-
week-old males and 10-week-old females (6 genes) as shown in table.  
 
Table 2 - Genes commonly dysregulated in TA of 3-week-old males and 10-week-
old females 
Gene name Gene ID 10-week-old females 3-week-old males
Glucuronidase, beta Gusb 2.27up 1.50up
Ubiquitin specific protease UBP43 Usp18 1.40up 1.44down
Transmembrane 9 superfamily member 2 Tm9sf2 1.46down 1.68up
Brain protein 44 Brp44 1.49down 1.76up
EPM2A (laforin) interacting protein 1 Epm2aip1 1.53down 1.50up
Hemoglobin, beta adult minor chain Hbb-b1 5.11down 1.89up
Tibialis anterior
 
 
In order to understand if the ACTA KI mouse is a good mouse model for NM, we 
grouped the dysregulated genes for each condition in the same functional groups 
as were found to be altered in the human patient study [217]: glucose metabolism, 
glycogen metabolism, fatty acid metabolism, cell cycle, transcription, ubiquitin 
related and muscle related genes. In almost all the conditions, we found altered 
genes belonging to the different functional groups.  
Subsequenty, we checked if proteins codified by altered genes were conserved in 
human as shown in the following tables (tables 3-8). 
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Table 3 – Dysregulated genes in DIA of 3-week-old males 
Illumina no. Gene name Symbol RefSeq Prot in human % identity in human Fold change
ILMN_2599997 RIP13 Ncor1 NP_006302.2 100 +2.25
ILMN_3041839 Pyruvate dehydrogenase (lipoamide) beta Pdhb NP_000916.2 100 +1.57
ILMN_2805945 Stress-associated endoplasmic reticulum protein 1 Serp1 NP_055260.1 100 -1.5
ILMN_2782964 Ectonucleotide pyrophosphatase/phosphodiesterase 1 allotype b Enpp1 NP_001543.2 92.1 -1.5
ILMN_2759108 DCXR mRNA for Dicarbonyl/L-Xylulose Reductase Dcxr NP_057370.1 100 -1.75
ILMN_2694955 Insulin-like growth factor binding protein 4 Igfbp4 NP_001543.2 100 -2.37
ILMN_1245103 Glucose-6-phosphatase, catalytic G6pc NP_000142.1 100 -2.44
ILMN_2710811 Glucokinase regulatory protein Gckr NP_001477.2 100 -2.64
ILMN_2840533 Aldolase 2, B isoform Aldob NP_000026.2 100 -2.64
ILMN_1237767 Hepatic nuclear factor 4, alpha Hnf4a NP_000448.3 100 -2.70
ILMN_1252185 Retinol binding protein 4, plasma Rbp4 NP_006735.2 100 -3.34
ILMN_2774160 Hydroxysteroid 11-beta dehydrogenase 1 Hsd11b1 NP_861420.1 100 -3.74
ILMN_1255497 Serine dehydratase Sds NP_006834.2 100 -3.76
ILMN_1221105 Glycine N-methyltransferase Gnmt NP_061833.1 100 -4.25
ILMN_1224012 Aldolase 2, B isoform Aldob NP_000026.2 100 -4.33
ILMN_2785586 Fructose bisphosphatase 1 Fbp1 NP_000498.2 84.9 -5.25
ILMN_2782964 Ectonucleotide pyrophosphatase/phosphodiesterase 1 allotype b Enpp1 NP_001543.2 92.1 -1.5
ILMN_1245103 Glucose-6-phosphatase, catalytic G6pc NP_000142.1 100 -2.44
ILMN_1221105 Glycine N-methyltransferase Gnmt NP_061833.1 100 -4.25
ILMN_2913078 Carbamoyl-phosphate synthetase 1 Cps1 NP_001116105.1 100 -4.75
ILMN_2739364 2-hydroxyacyl-CoA lyase 1 Hacl1 NP_036392.2 100 -1.55
ILMN_2611874 Protein tyrosine phosphatase-like A domain containing 1 Ptplad1 NP_057479.2 90.9 -1.72
ILMN_2966632 Cytochrome b-5 Cyb5 NP_683725.1 100 -1.78
ILMN_3136542 Glutaryl-Coenzyme A dehydrogenase Gcdh NP_000150.1 100 -1.78
ILMN_1216822 INSIG-2 membrane protein Insig2 NP_057217.2 100 -2.12
ILMN_1247156 Apolipoprotein A-II Apoa2 NP_001634.1 61.2 -2.19
ILMN_2649199 Hydroxyprostaglandin dehydrogenase 15 Hpgd NP_000851.2 89.8 -2.24
ILMN_1227398 Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Agt NP_000020.1 100 -2.52
ILMN_2641301 Apolipoprotein A-V Apoa5 NP_001160070.1 100 -2.56
ILMN_1237767 Hepatic nuclear factor 4, alpha Hnf4a NP_000448.3 100 -2.70
ILMN_1259009 Bile acid-Coenzyme A: amino acid N-acyltransferase Baat NP_001121082.1 69.4 -2.74
ILMN_2657980 Fatty acid amide hydrolase Faah NP_001432.2 84.1 -3.33
ILMN_1228469 Apolipoprotein C-I Apoc1 NP_001636.1 100 -3.75
ILMN_2648445 Solute carrier family 27 (fatty acid transporter), member 2 Slc27a2 NP_003636.2 100 -4.07
ILMN_2651539 Apolipoprotein C-III Apoc3 NP_000031.1 62.9 -4.20
ILMN_1252618 Acyl-Coenzyme A oxidase 2, branched chain Acox2 NP_003491.1 100 -4.39
ILMN_2875475 Glycolate oxidase Hao1 NP_060015.1 100 -4.48
ILMN_1214498 Cytochrome P450, family 2, subfamily d, polypeptide 22 Cyp2d22 NP_000097.2 75.8 -5.01
ILMN_2847061 Solute carrier family 27 (fatty acid transporter), member 5 Slc27a5 NP_036386.1 71.6 -5.22
ILMN_3009225 Apolipoprotein C-IV Apoc2 NP_000474.2 61.9 -5.53
ILMN_2599997 RIP13 Ncor1 NP_006302.2 100 +2.25
ILMN_1218761 Leucine zipper, putative tumor suppressor 2 Lzts2 NP_115805.1 100 +1.49
ILMN_2611821 Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform Ppp2ca NP_002706.1 99.7 +1.48
ILMN_2649199 Hydroxyprostaglandin dehydrogenase 15 Hpgd NP_000851.2 89.8 -2.24
ILMN_1237767 Hepatic nuclear factor 4, alpha Hnf4a NP_000448.3 100 -2.70
ILMN_2599997 RIP13 Ncor1 NP_006302.2 100 +2.25
ILMN_1214950 Myocyte enhancer factor 2C Mef2c NP_001124477.1 98.8 +2.06
ILMN_1253387 Kruppel-like factor 5 Klf5 NP_001721.2 100 +1.59
ILMN_2723108 TSC22-related inducible leucine zipper 1b Tsc22d1 NP_904358.2 100 +1.48
ILMN_2893993 LAG1 homolog, ceramide synthase 2 Lass2 NP_071358.1 92.4 -1.55
ILMN_2514689 Tumor necrosis factor receptor superfamily, member 8 Tnfrsf8 NP_001234.2 100 -1.70
ILMN_2926661 Nuclear receptor subfamily 1, group I, member 3 Nr1i3 NP_001070950.1 100 -2.04
ILMN_2826110 Mutant catalase Cat NP_001743.1 100 -2.06
ILMN_2693913 One cut domain, family member 2 Onecut2 NP_004843.2 99 -2.18
ILMN_1237767 Hepatic nuclear factor 4, alpha Hnf4a NP_000448.3 100 -2.70
ILMN_1224637 Forkhead box Q1 Foxq1 NP_150285.3 81.1 -3.35
ILMN_2727013 Nuclear receptor subfamily 1, group H, member 4 Nr1h4 NP_005114.1 100 -3.57
ILMN_1246758 Amplified in osteosarcoma Os9 NP_006803.1 100 -1.61
ILMN_1227398 Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Agt NP_000020.1 100 -2.52
ILMN_1243128 Apolipoprotein H Apoh NP_000033.2 100 -4.54
ILMN_1214950 Myocyte enhancer factor 2C Mef2c NP_001124477.1 98.8 +2.06
ILMN_1228718 Syndecan 1 Sdc1 NP_002988.3 100 -1.80
ILMN_2933463 Plasminogen Plg NP_000292.1 100 -5.07
ILMN_1234111 Vitronectin Vtn NP_000629.3 100 -4.32
ILMN_1252185 Retinol binding protein 4, plasma Rbp4 NP_006735.2 100 -3.34
ILMN_2426966 Tropomyosin 3, gamma Tpm3 NP_689476.2 87 +1.56
ILMN_2724585 Dystroglycan 1 Dag1 NP_004384.4 100 +1.65
Muscle
Glucose metabolism
Glycogen metabolism
Fatty acid metabolism
Cell cycle
Transcription
Ubiquitin related
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Table 4 - Dysregulated genes in DIA of 10-week-old males 
Illumina no. Gene name Symbol RefSeq Prot in human % identity in homo sapiens fold change
ILMN_1259322 Pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 NP_002603.1 100 +1.87
Cell cycle
ILMN_2620930 Damaged-DNA recognition protein 1 Ddb1 NP_001914.3 100 +1.41
ILMN_2776271 PCI domain containing 2 Pcid2 NP_060856.2 100 -1.44
ILMN_1257299 G0/G1 switch gene 2 G0s2 NP_056529.1 77.7 -2.27
ILMN_2749669 Nuclear receptor subfamily 1, group D, member 1 Nr1d1 NP_068370.1 95.8 +1.82
ILMN_2603178 Transcription factor A, mitochondrial Tfam NP_003192.1 63.6 +1.43
ILMN_2677921 Vasorin (Vasn) Dnaja3 NP_612449.2 100 -1.41
ILMN_2776271 PCI domain containing 2 Pcid2 NP_060856.2 100 -1.44
ILMN_2727472 ISL1 transcription factor, LIM/homeodomain Isl1 NP_002193.2 100 -1.48
ILMN_2450096 Zinc finger protein 30 Zfp30 NP_055713.1 85.3 -1.56
ILMN_2453620 Ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans) Ube2g1 NP_003333.1 100 +1.47
ILMN_2677921 Vasorin (Vasn) Dnaja3 NP_612449.2 100 -1.41
ILMN_3018017 Coxsackie virus and adenovirus receptor Cxadr NP_001329.1 89.9 -1.44
ILMN_2684515 Serine/arginine-rich protein specific kinase 3 Srpk3 NP_055185.2 100 +1.64
ILMN_2657543 Gamma sarcoglycan Sgcg NP_000222.1 100 +1.44
Glucose metabolism
Transcription
Ubiquitin related
Muscle
 
 
 
 
Table 5 - Dysregulated genes in DIA of 10-week-old females 
Illumina no. Gene name Symbol RefSeq Prot in human % identity in homo sapiens fold change
ILMN_2859847 Liver glycogen phosphorylase Pygl NP_002854.3 100 -2.06
ILMN_1250882 MLIP1 mRNA for lipoic acid synthase Lias NP_006850.2 100 +1.41
ILMN_2985282 enoyl-CoA delta isomerase Peci NP_996667.2 100 -1.40
ILMN_2846194 Enoyl Coenzyme A hydratase domain containing 2 Echdc2 NP_001185890.1 100 -1.45
ILMN_1228485 Casein kinase 2, alpha prime polypeptide Csnk2a2 NP_001887.1 98.9 +1.77
ILMN_2630438 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 Psmd7 NP_002802.2 100 +1.65
ILMN_3048503 Nipped-B homolog (Drosophila) Nipbl NP_597677.2 100 +1.55
ILMN_2622983 Dual specificity phosphatase 1 Dusp1 NP_004408.1 100 +1.52
ILMN_3139514 T-box 3, mRNA Tbx3 NP_057653.3 100 +1.49
ILMN_1225196 Transforming growth factor, beta 2 Tgfb2 NP_001129071.1 100 +1.45
ILMN_1236009 Calcium/calmodulin-dependent protein kinase II, beta Camk2b NP_742077.1 98.6 +1.44
ILMN_2971286 protein phosphatase 3, catalytic subunit, alpha isozyme Ppp3ca NP_000935.1 100 +1.41
ILMN_2794796 E2F transcription factor 4 E2f4 NP_001941.2 100 -1.40
ILMN_2640401 Platelet-activating factor acetylhydrolase, isoform 1b, beta1 subunit Pafah1b1 NP_000421.1 100 -1.53
ILMN_3048503 Nipped-B homolog (Drosophila) Nipbl NP_597677.2 100 +1.55
ILMN_1216416 Ring finger protein (C3H2C3 type) 6 Rnf6 NP_898864.1 100 +1.50
ILMN_3139514 T-box 3, mRNA Tbx3 NP_057653.3 100 +1.49
ILMN_1258406 Kelch-like ECH-associated protein 1 Keap1 NP_036421.2 100 +1.49
ILMN_2625451 Ankyrin repeat domain 1 (cardiac muscle) Ankrd1 NP_055206.2 100 +1.47
ILMN_1220834 Calmodulin binding transcription activator 2 Camta2 NP_055914.2 92.6 +1.45
ILMN_2691192 Retinoblastoma binding protein 7 Rbbp7 NP_001185648.1 100 +1.45
ILMN_2736347 Protein arginine N-methyltransferase 7 Prmt7 NP_061896.1 85.4 +1.44
ILMN_3023230 Jumonji domain containing 3 Kdm6b NP_001073893.1 92.7 +1.42
ILMN_2762514 Mesoderm induction early response 1, family member 2 Mier2 NP_060020.1 100 +1.42
ILMN_2741538 MAF1 homolog (S. cerevisiae) Maf1 NP_115648.2 100 +1.42
ILMN_2971286 Calcineurin catalytic subunit Ppp3ca NP_000935.1 100 +1.41
ILMN_1213307 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 1 Ctdsp1 NP_067021.1 100 -1.86
ILMN_2725428 DnaJ (Hsp40) homolog, subfamily B, member 2 Dnajb2 NP_006727.2 100 +1.69
ILMN_2630438 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 Psmd7 NP_002802.2 100 +1.65
ILMN_1216416 Ring finger protein (C3H2C3 type) 6 Rnf6 NP_898864.1 100 +1.50
ILMN_1255736 Valosin containing protein (Vcp) Vcp NP_004290.2 100 +1.42
ILMN_1220834 Calmodulin binding transcription activator 2 Camta2 NP_055914.2 92.6 +1.45
ILMN_3139514 T-box 3, mRNA Tbx3 NP_057653.3 100 +1.49
ILMN_2971286 Calcineurin catalytic subunit Ppp3ca NP_000935.1 100 +1.41
ILMN_1225196 Transforming growth factor, beta 2 Tgfb2 NP_001129071.1 100 +1.45
ILMN_2853658 Pelota homolog (Drosophila) (Pelo) Itga1 NP_057030.3 96.4 +1.41
ILMN_2684515 Serine/arginine-rich protein specific kinase 3 Srpk3 NP_055185.2 100 +1.45
ILMN_1235230 PDZ and LIM domain 3 Pdlim3 no +1.42
ILMN_2625451 Ankyrin repeat domain 1 (cardiac muscle) Ankrd1 NP_055206.2 100 +1.47
Glycogen metabolism
Fatty acid metabolism
Cell cycle
Transcription
Ubiquitin related
Muscle
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Table 6 - Dysregulated genes in TA of 3-week-old males 
Illumina no. Gene name Symbol RefSeq Prot in human % identity in homo sapiens fold change
ILMN_2674720 Prostaglandin E synthase 3 (cytosolic) Ptges3 NP_006592.3 98.8 +1.70
ILMN_2703657 Dihydrolipoamide dehydrogenase Dld NP_000099.2 100 +1.74
ILMN_2674720 Prostaglandin E synthase 3 (cytosolic) Ptges3 NP_006592.3 98.8 +1.70
ILMN_2704826 Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) Acaa2 NP_006102.2 100 -1.60
ILMN_1216211 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 Psmd12 NP_078968.3 96.2 +1.69
ILMN_1239860 SRA stem-loop interacting RNA binding protein Slirp NP_112487.1 70.8 +1.92
ILMN_2728830 TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated factor Taf13 NP_005636.1 100 +1.64
ILMN_2903440 Heterogeneous nuclear ribonucleoprotein D-like Hnrpdl NP_112740.1 99.7 +1.63
ILMN_3007959 GDNF-inducible zinc finger protein Gzf1 NP_071927.1 82.6 +1.62
ILMN_1252757 Myeloid/lymphoid or mixed-lineage leukemia Mllt3 NP_004520.2 98.6 +1.55
ILMN_1252121 SAFB-like, transcription modulator Sltm NP_079031.2 91.2 +1.53
ILMN_2680262 Polymerase (RNA) II (DNA directed) polypeptide G Polr2g NP_002687.1 100 +1.52
ILMN_2650040 MKIAA1041 protein Foxj3 NP_055762.3 94.7 +1.48
ILMN_2637365 Mediator of RNA polymerase II transcription, subunit 28 homolog Med28 NP_079481.2 100 +1.46
ILMN_3009572 Thioredoxin 1 Txn1 NP_003320.2 100 +1.45
ILMN_1254256 Actin-like 6A Actl6a NP_004292.1 100 +1.45
ILMN_1238852 TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated factor Taf12 NP_001128690.1 100 +1.44
ILMN_1240149 Vacuolar protein sorting 36 Vps36 NP_057159.2 100 +1.43
ILMN_2845208 Leucine-rich PPR-motif containing Lrpprc NP_573566.2 100 +1.42
ILMN_2765015 Embryonic ectoderm development Eed NP_003788.2 100 +1.42
ILMN_2953700 MAD homolog 1 Smad1 NP_001003688.1 99.1 +1.40
ILMN_3148662 Splicing factor, arginine/serine-rich 5 Sfrs5 NP_008856.2 97.4 -1.42
ILMN_2870320 Protein kinase D2 Prkd2 NP_001073349.1 100 -1.44
ILMN_1256775 Thyroid hormone responsive SPOT14 homolog Thrsp NP_003242.1 85.5 -1.46
ILMN_1216211 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 Psmd12 NP_078968.3 96.2 +1.69
ILMN_2933914 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 Psmd14 NP_005796.1 100 +1.60
ILMN_2465770 Ubiquitin specific peptidase 14 Usp14 NP_005142.1 100 +1.44
ILMN_2793503 Ubiquitin carboxyl-terminal esterase L5 Uchl5 NP_057068.1 100 +1.41
ILMN_3131679 Ubiquitin specific protease UBP43 Usp18 NP_059110.2 100 -1.44
ILMN_1241976 Ubiquitin associated domain containing 1 Ubac1 NP_057256.2 100 +1.73
ILMN_2623859 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 Abcc9 NP_005682.2 100 +1.50
ILMN_2660766 CD59b antigen Cd59b NP_000602.1 100 +1.48
Glycogen metabolism
Fatty acid metabolism
Cell cycle
Transcription
Ubiquitin related
Muscle
 
 
 
Table 7 - Dysregulated genes in TA of 10-week-old males 
Illumina no. Gene name Symbol RefSeq Prot in human % identity in homo sapiens fold change
ILMN_2785586 Fructose bisphosphatase 1 Fbp1 NP_000498.2 84.9 +1.43
ILMN_2738082 Adiponectin, C1Q and collagen domain containing Adipoq NP_001171271.1 100 -2.03
ILMN_2695964 Leptin Lep NP_000221.1 100 -2.29
ILMN_2738082 Adiponectin, C1Q and collagen domain containing Adipoq NP_001171271.1 100 -2.03
ILMN_2695964 Leptin Lep NP_000221.1 100 -2.29
ILMN_2763115 Cell division cycle 34 homolog Cdc34 NP_004350.1 100 +1.40
ILMN_1215252 Bone morphogenetic protein 4 Bmp4 NP_001193.2 100 -1.42
ILMN_3150811 TSC22 domain family, member 3 Tsc22d3 NP_932174.1 100 -1.41
ILMN_1215252 Bone morphogenetic protein 4 Bmp4 NP_001193.2 100 -1.42
ILMN_2656498 Forkhead box O1 Foxo1 NP_002006.2 100 -1.44
ILMN_2695964 Leptin Lep NP_000221.1 100 -2.29
ILMN_2763115 Cell division cycle 34 homolog (S. cerevisiae) Cdc34 NP_004350.1 100 +1.40
ILMN_2629582 Plasminogen activator, urokinase Plau NP_002649.1 100 -1.40
ILMN_2738082 Adiponectin, C1Q and collagen domain containing Adipoq NP_001171271.1 100 -2.03
ILMN_2697304 Elastin Eln NP_000492.2 75.5 +1.40
ILMN_1231104 NF1GRP mRNA for neurofibromatosis type-1-GTPase activating-protein type IV Nf1 NP_001035957.1 98.5 -1.40
ILMN_3150811 TSC22 domain family, member 3 Tsc22d3 NP_932174.1 100 -1.41
ILMN_1215252 Bone morphogenetic protein 4 Bmp4 NP_001193.2 100 -1.42
ILMN_2440823 Tenascin XB (Tnxb) Clcn1 NP_061978.6 100 -2.05
Glucose metabolism
Fatty acid metabolism
Cell cycle
Transcription
Ubiquitin related
Muscle
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Table 8 - Dysregulated genes in TA of 10-week-old females 
Illumina no. Gene name Symbol RefSeq Prot in human % identity in homo sapiens fold change
ILMN_2647627 Protein phosphatase 1 (dis2m2) Ppp1cb NP_996759.1 99.7 -2.09
ILMN_2647627 Protein phosphatase 1 (dis2m2) Ppp1cb NP_996759.1 99.7 -2.09
ILMN_2613908 Arachidonate 12-lipoxygenase Alox12 NP_000688.2 85.5 +1.72
ILMN_2741117 Ankyrin repeat domain 23 Ankrd23 NP_659431.5 82.6 +1.40
ILMN_2592925 Monoglyceride lipase Mgll NP_009214.1 100 -1.40
ILMN_2622671 Acyl-CoA synthetase long-chain family member 1 Acsl1 NP_001986.2 100 -1.65
ILMN_2678547 Lysophospholipase 1 Lypla1 NP_006321.1 91.7 -1.71
ILMN_1239724 Proteasome (prosome, macropain) subunit, beta type 1 Psmb1 NP_002784.1 100 +1.82
ILMN_2676181 Sirtuin 2 Sirt2 NP_036369.2 100 +1.60
ILMN_1249224 Tumor protein D52-like 1 Tpd52l1 NP_003278.1 90.7 +1.50
ILMN_2725429 U7 snRNP-specific Sm-like protein LSM10 Lsm10 NP_116270.1 90.8 +1.43
ILMN_2763602 Macrophage erythroblast attacher Maea NP_001017405.1 98.7 -1.44
ILMN_2647627 Protein phosphatase 1 (dis2m2) Ppp1cb NP_996759.1 99.7 -2.09
ILMN_2676181 Sirtuin 2 Sirt2 NP_036369.2 100 +1.60
ILMN_1246841 Avian reticuloendotheliosis viral (v-rel) oncogene related B Relb NP_006500.2 89.9 +1.51
ILMN_1253650 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 Smarca1 NP_003060.2 100 +1.50
ILMN_2778111 Ets variant gene 4 (E1A enhancer binding protein, E1AF) Etv4 NP_001073143.1 100 +1.49
ILMN_2938047 Ets variant gene 5 Etv5 NP_004445.1 100 +1.49
ILMN_2909248 Vestigial like 2 homolog (Drosophila) Vgll2 NP_872586.1 100 +1.47
ILMN_2825803 Poly (ADP-ribose) polymerase family, member 14 Parp14 NP_060024.2 64.3 +1.44
ILMN_3086192 Y box protein 2 Ybx2 NP_057066.2 100 -1.63
ILMN_2647605 SET and MYND domain containing 1 Smyd1 NP_938015.1 100 -1.92
ILMN_1239724 Proteasome (prosome, macropain) subunit, beta type 1 Psmb1 NP_002784.1 100 +1.82
ILMN_2433990 Ubiquitin specific protease UBP43 Usp18 NP_059110.2 100 +1.40
ILMN_2593356 Cereblon (Crbn), transcript variant 1 Crbn NP_057386.2 100 -1.48
ILMN_3005873 Sortilin 1 Sort1 NP_002950.3 100 +1.57
ILMN_2599748 MAP Kinase Map2k6 NP_002749.2 100 -1.46
ILMN_2613908 Arachidonate 12-lipoxygenase Alox12 NP_000688.2 85.5 +1.72
ILMN_2674213 L-type calcium channel beta 1C subunit Cacnb1 NP_000714.3 100 +1.56
ILMN_1223437 GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus Gnas NP_536350.2 100 -1.47
ILMN_2678218 Matrix metallopeptidase 2 Mmp2 NP_004521.1 100 +1.82
ILMN_2741117 Ankyrin repeat domain 23 Ankrd23 NP_659431.5 82.6 +1.40
Muscle
Glucose metabolism
Glycogen metabolism
Fatty acid metabolism
Cell cycle
Transcription
Ubiquitin related
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2.3 microRNA expression profiling 
2.3.1 Selection of microRNAs  
Expression levels of 20 selected miRs out of the 153 miRs that were found to be 
dysregulated in NM patients were investigated in our mouse models. The criteria 
for selection of miRs was that they had to be uniquely and more than 2.5 fold 
upregulated in NM patients, or, if upregulated also in other neuromuscular 
diseases, show a significantly higher fold change in NM patients. Although let-7a, 
let-7f, let-7d, and miR-188 were less than 2.5 times upregulated in NM patients, 
they were included because they were found to be upregulated in our initial studies 
using the quantimiR profiling System. The selected miRs are shown in table. 
 
 
Table 9. miRs selected from the Eisenberg et al paper (PNAS,2007) 
 
2.3.2 miR expression in TA and DIA muscles from Acta1(H40Y)KI mice  
The expression levels of selected miRs were determined in Acta1(H40Y)KI mice 
and Tmslow(Met9Arg)Tg (Tg) mice using the QuantiMiR RT Kit (Systems 
Biosciences) in combination with the Power SYBR Green PCR Master mix (Applied 
Biosystems). To allow us to study the miR expression profile at early and late 
stages of NM, we chose to perform our studies on TA and DIA from 3- and 10-
week-old KI male mice as well as 8-month-old TPM3Tg (Tg) mice compared to 
littermate controls. As shown in paragraph 1.2.4.2 KI males die around 10 weeks of 
age, while females show a mild phenotype around that age. For this reason we 
considered the males a better model for studying miR expression levels during the 
progression of NM. As presented above, the same time points were chosen for our 
gene expression studies, and we used the same samples for the miR and gene 
expression studies, allowing us to compare miR and gene expression profiles. For 
the less affected Tg mice we chose a time point of 8 months, which is around the 
time where they start showing signs of the disease. A gene expression study on 8-
month-old Tg mice has previously been published [215].  
hsa-name SIGNATURE BMD DMD FSHD LGMD2A LGMD2B Miyoshi NM DM PM IBM
hsa_miR_368 shared 8.56 4.85 6.33 7.77 4.39 30.09 4.53
hsa_miR_381 shared 7.63 3.41 6.20 2.28 23.24 3.37 3.30
hsa_miR_410 shared 2.96 11.24
hsa_miR_127 shared 2.66 9.36 2.38
hsa_miR_493_5p unique 7.44
hsa_miR_409_5p unique 7.10
hsa_miR_128b unique 4.82
hsa_miR_337 unique 3.85
hsa_miR_181c unique 3.73
hsa_miR_483 unique 2.30
hsa_let_7f unique 1.89
hsa_let_7d unique 1.83
hsa_miR_188 unique 1.82
hsa_let_7a unique 1.60
hsa_miR_376a shared 5.77 3.48 5.72 2.44 14.78
hsa_miR_542_5p shared 1.93 14.75 2.27
hsa_miR_98 unique 2.52
hsa_miR_199a shared 3.90 4.35 4.30 5.09 2.66 5.14 3.64 5.47
hsa_miR_196a unique 10.29
hsa_miR_181a shared 1.52 1.65 5.35
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RNA was extracted using Trizol reagent (Invitrogen) and the integrity of the RNA 
was checked on a bioanalyzer (Agilent). Only samples with a RIN value ≥ 8 were 
included in the study. qRT-PCR was performed in triplicates on three biological 
replicates for each miR and U6 and U1 (small RNAs) were used as endogenous 
controls for normalization. Fold changes were calculated based on average miR 
expression levels in WT littermate controls. The miR expression levels in mutant 
mice were not pooled because of too much difference between mice. 
miR expression levels in the different groups are shown in table 10.  
-  
 
Table 10 -. Upregulated miRs are shown in red, while downregulated miRs are 
shown in green. 
 
2.4 Target prediction 
In order to predict putative targets of the 20 studied miRs we applied prediction 
algorithms based on complementary base-pair extension and thermodynamic 
evaluation of the complex (miRanda, TargetScan and RNAhybrid packages). 
Subsequently, the obtained target list was further refined by adopting the PITA 
target prediction method to search for accessible sites (for more details about 
target prediction tools see paragraph 1.3.6 in introduction). Since the majority of 
miRs were predicted to target a very large number of transcripts, we conducted an 
enrichment analysis over Gene Ontology terms to narrow down the list of targets 
and focus on biological functions that were most signiﬁcantly aﬀected by multiple 
miRs and were related to NM disease. Target prediction was performed against 
17,231 mouse genes (genome assembly mm9 -NCBI37) and putative target genes 
were filtered for functional annotation in Gene Ontology (UCSC) that describe 
genes involved in the Nemaline Myopathy (Acta1;Cfl2;Neb;Tnnt1;Tpm1;Tpm2). 
Predicted targets of dysregulated miRs and the functional categories that they 
belong to are shown in table 5. In particular, predicted targets involved in muscle 
contraction and actin binding could be particularly interesting since the muscle 
weakness associated with NM has been shown to be due to altered cross-bridge 
cycling kinetics [216].  
 
 
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
miR-376c 10.42 14.16 59.63 0.31 0.71 0.11 26.70 12.42 3.79 0.01 0.01 0.00 3.44  - 1.03 2.00  - 5.00
miR-381 2.02 1.97 0.71 4.42 14.32 2.36 2.64 2.13 1.30 0.35 0.53 0.02  - 1.00 1.41  - 1.52 0.85
miR-410 0.50 0.88 0.06 1.01 4.47 0.34 1.63 0.63 0.91  -  -  -  -  -  -  -  -  -
miR-127 0.62 1.05 0.07 2.47 12.90 0.58 4.05 1.70 1.28 0.47 0.68 0.13 0.68  - 0.80 0.76  - 1.06
miR-493 1.32 1.53 2.52 2.40 4.31 0.43 4.31 2.25 0.93 0.29 0.81 0.05 0.98 0.44  - 3.16 1.14  -
miR-409-5p 1.07 1.52 0.48 1.99 6.97 0.96 2.54 1.49 1.35  -  -  -  - 0.55  -  - 1.43  -
miR-128 0.48 0.68 0.19 0.32 1.55 0.58 0.67 0.37 0.31 0.28 0.84 0.08 1.72 3.65 1.55 2.45 2.00 2.17
miR-337-3p 0.82 2.02  - 3.82 14.52 1.48 1.92 0.85 1.49 0.63 2.34 0.21  - 7.29 0.69  -  - 3.32
miR-181c 1.83 1.20 0.64 0.45 1.84 0.13 0.84 0.92 0.41 0.07 0.52 0.00 1.36 1.70 0.75 1.71 1.11 1.05
miR-483 0.73 2.38 4.38 0.63 2.53 0.80 1.47 2.54 1.64 0.02 0.09 0.02 1.60 0.33 0.15  - 0.09 1.42
let-7f 0.30  - 1.26 1.94 0.49 0.47 1.08 0.58 0.38 0.42 0.32 0.05 1.57 3.13 0.53 0.91 0.04 1.71
let-7d 2.43 0.55 22.98 5.96 0.55 11.46 5.35 0.45 2.75 2.22 0.12 0.41 1.49 0.46 0.17 1.51 0.11 0.76
miR-188-5p 0.75 0.70 2.38 0.96 1.35 3.24 2.85 1.08 4.23 0.10 0.15 0.98  - 1.24 0.08 1.24
let-7a 1.78 0.86 10.40 1.35 1.56 0.54 1.82 1.89 0.25 0.05 0.25 0.06 1.49 0.48 0.13 1.51 0.07 0.90
miR-376a - - - - - - - - - - - -  -  -  -  -  -  -
miR-542-5p - - - - - - - - - - - -  -  -  -  -  -  -
miR-98 0.45 0.61 0.31 0.62 2.10 0.38 0.81 2.41 0.22 0.20 1.52 0.14 1.49 0.40 0.13 1.42 0.22 1.89
miR-199a5p 0.63 1.84 1.13 4.21 2.09 1.33 0.85 2.37 0.39 1.51 4.74  - 1.89 0.12  - 10.68 1.55
miR-196a - - - - - - 2.87 1.25 1.28 0.67 1.38 0.48  - 0.10  - 2.14 0.41 2.69
miR-181a 1.29 1.00 0.54 0.97 1.88 0.85 1.23 0.47 0.55 0.30 0.41 0.28 1.17 143.37 0.12 2.21 7.60 1.12
KI DIA 3weeks KI DIA 10weeks KI TA 3weeks KI TA 10weeks Tg DIA 8months Tg TA 8months
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Table 11.Functional categories of predicted targets of dysregulated miRs 
  
GO terms number 
predicted 
targets 
number 
predicted 
and conserved 
targets 
Actin binding 200 49 
Actin cytoskeleton 53 15 
Actin filament 11 2 
Actin filament binding 2 0 
Cardiac muscle contraction 12 2 
Filamentous actin 8 4 
Muscle contraction 8 2 
Myofibril 2 0 
Regulation of muscle contraction 11 1 
Sarcomere 6 0 
Sarcomere organization 1 0 
Skeletal muscle fiber development 4 0 
Stress fiber 17 7 
Tropomyosin binding 4 0 
Ventricular cardiac muscle morphogenesis 4 1 
Z disc 10 2 
 
 
 
 
The number of predicted targets was restricted when we considered only targets 
conserved in human. 
 
 
 
 
In particular, miR-381, which is highly upregulated in human NM muscle, appeared 
to be the most interesting miR as it has many potential targets in skeletal muscle 
that are conserved between mouse and human (table 12).  
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Table 12 - miR381 targets  
 
2.5 In vitro target validation: luciferase assay 
To determine whether predicted targets were real targets, selected miR-381 targets 
of interest (Actg1, Cd2ap, Tln2, Tpm1, Trim63, Trpm7) were tested by 
experimental validation in vitro. The 3‟UTR of predicted targets were cloned 
downstream of the luciferase gene in the pGL3-promoter vector (Promega) and co-
transfected with an expression plasmid containing miR-381 fused to Green 
Fluorescent Protein into 293 myoblasts. Significant changes in TRPM7 and 
TRIM63 luciferase expression levels were observed (fig 20), while no changes in 
expression levels of the other tested potential targets were found.  
  
Fig.20 miR-381 regulation of Trpm7 and TRIM63 gene expression, shown by the 
luciferase assay 
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3. DISCUSSION 
Nemaline Myopathy (NM) is a heterogeneous neuromuscular disease both from a 
clinical and a genetic point of view. Causative mutations have been identified in six 
different genes encoding thin filament proteins, including Acta1, skeletal muscle 
alpha-actin, Neb, nebulin, Tpm3, slow alpha-tropomyosin (alpha-3 chain), Tpm2, 
beta tropomyosin, Tnnt1, slow troponin T, and Cfl2, cofilin2. The disease is 
characterized by muscle weakness and the presence of protein aggregates called 
nemaline bodies. Furthermore, dependent on the causative mutation and the 
severity of the disease, NM has been associated with respiratory problems, muscle 
atrophy, and an increase in type I fibers. .The heterogeneity of the disease makes 
the diagnosis difficult and reduces the possibility for developing a therapy. Thus, 
more insights into molecular pathways underlying the pathology that are commonly 
affected in NM patients may open up for new treatment options targeted towards 
commonly affected pathways. 
 
During the last years, gene expression studies on patients [217] and a  mouse 
model, Tmslow(Met9Arg)Tg (Tg) [215] of NM have been carried out, providing 
information about the gene expression changes associated with NM. However, the 
Tg mouse presents a mild form of the disease, and alterations present in the more 
severe cases of NM may therefore have been missed in that study. In our study we 
performed a gene expression analysis on the ACTA (H40Y)KI (KI) mouse model, 
which shows a more severe phenotype compared to the Tg mouse. In order to 
analyze changes in gene expression at an early and late stage of the disease, we 
performed our analyses on both 3- and 10-week-old mice. Due to a milder 
phenotype in KI females compared to KI males, the analysis of 10-week-old mice 
was performed both on males and females. The gene expression analysis was 
conducted on diaphragm (DIA) and tibialis anterior (TA) of wildtype (WT) and 
knockin (KI) mice. 
3.1 Gene expression study 
The results discussed here are still preliminary since the gene expression 
experiment has just recently been performed. One approach for analyzing the gene 
expression study would be to focus on genes that are commonly dysregulated at all 
the different conditions. However, this kind of analysis would be too restricted and 
we could miss genes that are altered in one condition and not in others, which 
could be still of interest. To get a general overview over which genes are altered 
and in which pathways they are involved, we independently analyzed the results 
from the three different conditions (3-week-old males, 10-week-old males, and 10-
week-old females) in the two different muscles (DIA and TA).  
 
Interestingly, the DIA of 3-week-old males showed the highest level of altered gene 
expression in our analysis, presenting 493 dysregulated genes with a significant 
fold change over 1.4, while 41 and 83 genes were dysregulated in DIA of 10-week-
old males and females, respectively. TA of 3-week-old males was the most 
affected as well with 122 dysregulated genes with a significant fold change over 
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1.4 versus 46 and 102 genes dysregulated in 10-week-old males and females, 
respectively. The high number of dysregulated genes in 3-week-old males genes 
suggests the impairment of several processes with the early onset of the disease, 
while maybe only specific pathways remain altered later on in the late stage of the 
disease. The fact that the DIA shows the most altered gene expression pattern is 
consistent with the fact that the DIA is generally the most affected muscle in 
neuromuscular diseases, most likely because the DIA as opposed to other muscles 
is continuously used from the time of birth.  
 
In our analyses we particularly focused on the DIA of 3-week-old males in order to 
reveal altered pathways that may be relevant for the early onset of NM. 
Interestingly, 22 genes, which were among the most changed genes, were involved 
in the same pathway: the coagulation cascade. Normally coagulation is activated 
immediately after an injury to the blood vessels that damages the endothelium 
lining the vessels and causes the exposure of the tissue factor protein. Two 
different processes (intrinsic and extrinsic) culminate in fibrin clot formation. In KI 
mice the coagulation cascade is impaired in both its pathways, with a general 
downregulation of several key genes for the formation of clots of fibrin. In particular, 
serpin proteins, which are proteases activated in the cascade to cut the serine-rich 
domains of the inactive form of coagulation proteins, are downregulated. One such 
protein is an anti-thrombin; thrombin plays a crucial role in the conversion of 
fibrinogen to fibrin during the coagulation process. Based on the downregulation of 
anti-thrombin serpin proteins, we would expect thrombin to be upregulated.  
However, thrombin levels are unchanged in KI DIA compared to WT, suggesting 
that other factors regulate its expression. Also fibrinogen is downregulated. During 
infection, activation of coagulation and subsequent fibrin deposition are essential 
parts of the host‟s defense in order to contain the invading microorganisms and the 
subsequent inflammatory response, and to avoid sepsis. Impairment of the 
coagulation cascade could affect the pathway of the complement system, possibly 
causing increased inflammation. However, further analyses need to be done to 
better elucidate these pathways and to reveal if this pathway is impaired also in the 
late stage of the disease. 
Comparison of the gene expression analyses in the two different muscles, DIA and 
TA at the same stage, revealed only few commonly dysregulated genes. This 
finding confirms the results of the gene expression study conducted on the Tg 
mouse [215] in which different muscles, TA, gastrocnemius (GAS), plantaris (PLT), 
DIA, and extensor digitorum longus (EDL), were analyzed and DIA showed a 
peculiar alteration of the gene expression, distinct from all the other muscles.  
Comparison of dysregulated genes between different conditions (3-week-old 
males, 10-week-old males and females) revealed that 3-week-old males shared the 
highest number of genes with 10-week-old females in both DIA and TA. This 
reflects the difference between males and females in developing the disease, with 
the genetic expression pattern of old females closer to young than to old males, in 
agreement with the delayed development of the disease in females.  
Interestingly, the only gene that was commonly downregulated in 3- and 10-week-
old males was complement component 2 (C2), which is involved in the pathway of 
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the complement system during inflammation, suggesting that this pathway is 
impaired also in 10-week-old males. 
The presence of such a low number of altered genes shared between different 
conditions in terms of muscle type, age, and gender was unexpected. However, we 
observed that, even if the specific dysregulated genes are different, some 
pathways, such as metabolic pathways, are commonly dysregulated under different 
conditions, suggesting that the altered genes can be different, while their biological 
function may be similar.  
In particular, alterations in seven specific functional categories (glucose 
metabolism, glycogen metabolism, fatty acid metabolism, cell cycle, transcription, 
ubiquitin, and muscle related genes) were investigated, to look for similarities with 
the human gene expression analysis in which these categories showed impaired 
gene expression patterns [217]. As reported in table in tables 3-8, genes belonging 
to all the seven categories were dysregulated in the DIA of 3-week-old males, while 
glycogen and fatty acid metabolism were unaltered in the DIA of 10-week-old 
males; the DIA of 10-week-old females did not show altered expression of genes 
involved in glucose metabolism. In the TA, glucose metabolism was not impaired in 
3-week-old males and in 10-week-old females, while in 10-week-old males 
glycogen metabolism was not impaired, suggesting once again a closer gene 
expression pattern between young males and old females than with old males. 
Among the altered genes almost all encode proteins that are highly conserved in 
human. 
When compared to the human study [217], some genes that were altered in KI 
mice were the murine homologues (sometimes other isoforms) of human 
dysregulated genes; in DIA, Fbp1, Cyp2d22, Ppp2ca, Nr1i3, Nr1h4 (3-week-old 
males); Nr1d1, Zfp30, and Ube2g1 (10-week-old males); Dusp1, Ppp3ca and 
Tgfb2 (10-week-old females). In TA, Usp18, and Ubac1 (3-week-old males); Fbp1 
(10-week-old males) Ppp1cb, Sirt2, and Usp18 (10-week-old females). 
Based on our preliminary analysis of gene expression in the KI mouse model, this 
is a better model for NM than the Tg mouse, since like in the human study, an 
impairment in metabolic pathways was found in KI mice which was not found in Tg 
mice.  
3.2. MicroRNA expression study 
In a study published in 2007 in PNAS [212], a peculiar miR expression pattern was 
found in NM patients compared to other neuromuscular diseases (Duchenne 
muscular dystrophy, Becker muscular dystrophy, facioscapulohumeral muscular 
dystrophy, limb-girdle muscular dystrophies types 2A and 2B, Miyoshi myopathy, 
polymyositis, dermatomyositis, and inclusion body myositis). The presence of 150 
dysregulated miRs of which 36 were uniquely dysregulated in NM patients, 
suggests an important role of miRs in the disease, leading us too hypothesize their 
involvement in the regulation of pathological pathways underlying NM. 
In our study expression levels of 20 selected miRs were investigated in 3- and 10-
week-old KI males to study their expression in relation to the development of the 
disease. As evident from Tables 3-8, many of the miRs that have been found to be 
dysregulated in human NM patients were also found to be dysregulated in our 
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mouse models. However, we observed a high number of individual differences in 
miR expression levels that sometimes followed the same trend 
(upregulation/downregulation) in biological replicates with a variability in fold 
change, but also often went in opposite directions, i.e. downregulated in one 
replicate and upregulated in another. It appears that one of the KI replicates in 3-
week-old mice is an outlier, showing a different miR expression pattern compared 
to the other replicates. However, it is strange that the dysregulation of miRs in that 
sample is not random, as it  shows downregulation of most of the miRs compared 
to the average expression levels in the controls. One explanation for the big 
variability in miR expression levels, could be that the development of the disease is 
different between individuals; during the collection of muscles of WT and KI mice 
we noticed that while some KI mice showed a clear phenotype, no visible 
phenotype was observed in others.  
In the TA of 10-week-old KI males, the expression levels of most of the studied 
miRs were consistently downregulated. This could indicate a complete change in 
gene expression regulation by miRs, but further analysis are required to address 
the biological meaning of this observation. 
Moreover, we observed that the expression of many of the miRs that are 
dysregulated in NM patients are likewise altered in KI mice, while they are less 
affected in Tg mice, showing once again that the KI mouse model better 
recapitulate the NM patient phenotype than the Tg mouse model 
Of particular interest was miR-381, which was overexpressed in the different 
conditions and was predicted to target muscle specific genes involved in the 
pathology of NM. In particular, many of the predicted targets of miR-381 are 
involved in muscle contraction and actin binding, which could be of particular 
interest since the muscle weakness associated with NM has been shown to be due 
to altered cross-bridge cycling kinetics [216]. The human miR-381 has been 
reported to be an oncomiR that by regulating LRRC4 (a glioma tumor suppressor) 
increases the in vitro and in vivo proliferation of glioma cells [218]. No data are 
reported in the literature about its expression in skeletal muscle, except its high 
upregulation in NM patients.  
Two of the predicted miR-381 targets, TRIM63 and TRPM7, were validated in vitro 
by an luciferase assay. 
Trim63, also known as MURF1 (Muscle specific RING Finger E3 ligase), is a 
member of the ubiquitin system. Muscle degeneration, due to inactivity, 
denervation, or severe catabolic states, activates the ubiquitin–proteasome protein 
degradation pathway and the induction of many of its component enzymes [15, 25–
28]; in NM an impairment in ubiquitin related genes has been reported in human 
patients [217], which was also found in KI mice at all the different conditions. 
Moreover, it has been reported that Trim63 is differentially expressed under 
conditions of muscle atrophy [29], and that skeletal muscle atrophy occurs in 
Nemaline Myopathy [219]. In the luciferase assay, the expression level of the 
Renilla luciferase fused to the 3‟UTR of Trim63 was downregulated by 25% when 
cotransfected with miR-381. However in our gene expression analysis on KI mice 
we did not observe any differences in Trim63 expression levels. Since depending 
on complementarity, miRs often affect their targets at the translational level, it is 
possible that miR-381 affects Trim63 at the protein level but not at the mRNA level. 
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Trmp7 (transient receptor potential cation channel, subfamily M, member 7) 
belongs to the TRP superfamily of ion channels that is a structurally defined group 
of cation channels showing an enormous functional diversity. TRPM7 is the most 
frequent non-voltage gated cation channel in skeletal muscle [220]. Though 
TRPM7 preferentially conducts Mg
2+
 it provides a significant Ca
2+
entry pathway 
[47]. Although the possibility of altered Ca
2+
 regulation has not been studied in NM, 
it has previously been suggested that muscle weakness can be caused by a 
reduced Ca
2+
 sensitivity of the contractile apparatus in this disease [221; 222] and 
the idea is reinforced by the fact that NM can also be caused by mutations in 
tropomyosin and troponin [223]. In the luciferase assay the expression level of the 
Renilla luciferase fused to the 3‟UTR of TRPM7 was downregulated by 30% when 
cotransfected with miR-381. The TRPM7 mRNA level was unchanged in the gene 
expression study on KI mice and also in this case further analyses at the protein 
level need to be performed. 
We hypothesized that alterations in miR expression levels influence gene 
expression levels by miR-mediated regulation. On the other hand, it is possible that 
upregulation of miR-381 and the dysregulated miR expression pattern in general is 
a consequence of secondary gene pathways that underlie the disease. In this 
respect, it is possible that a dysregulation of a large number of genes occurs at the 
initial stage the disease, causing the overexpression of miRs to modulate the gene. 
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4. CONCLUSION 
In the present study gene and miR expression levels have been investigated in a 
mouse model of Nemaline Myopathy (NM). The mouse model used in the analysis 
was the ACTA(H40Y)KI (KI) mouse, that well recapitulates the NM phenotype. 
Interestingly, the KI mouse shows differences in disease development between 
males and females, with males exhibiting early onset of the disease resulting in 
death from around 10 weeks of age and females still showing a mild phenotype 
around 10 weeks of age. The molecular basis for this difference was investigated in 
the gene expression study.  
The gene expression analysis was performed in triplicates on 3-week-old males 
and 10-week-old males and females. However, in two cases, the diaphragm (DIA) 
of 10-week-old males and the tibialis anterior (TA) of 10-week-old females, there 
was a bad correlation between a WT and a KI sample and the other samples and 
we therefore performed the analysis at these conditions on duplicates instead of 
triplicates. Although we performed student‟s t-test and only considered gene 
expression changes with a p-value < 0.05, we will  perform gene expression 
analysis on additional samples in order to perform all analyses on triplicates. 
Moreover, the results will be confirmed by real-time PCR for dysregulated genes on 
the same samples. 
The preliminary analysis of the gene expression results showed impairment in the 
coagulation cascade in the DIA of 3-week-old males with 22 genes dowregulated in 
the pathway. It would be interesting to determine the levels of the proteins encoded 
by the dysregulated genes and to investigate if the same pathway or related 
pathways are impaired in older males. 
The main feature of KI mice compared to Tg mice, a mouse model of a mild form of 
NM, is the dysregulation of genes involved in metabolic pathways that were also 
found to be dysregulated in human patients [217]. This suggests that the KI mouse 
model better recapitulates NM than the Tg mouse model. However, these results 
need to be investigated in more detail. 
The miR expression analysis of KI mice revealed the dysregulation of a group of 
miRs that has been reported dysregulated in human patients [217]. Of the 
dysregulated miRs, miR-381 was of particular interest based on its high 
upregulation in human and in mouse as well as its predicted targets. 
Two targets of miR-381 were validated in vitro by luciferase assay: a gene involved 
in calcium homeostasis (TRPM7) and a gene involved in the ubiquitin system 
(Trim63/MURF1). The specific interaction of miR-381 with the 3‟UTR of TRPM7 
was confirmed after mutagenesis of its miR interaction site in the 3‟UTR. 
Mutagenesis will likewise be performed for Trim63. In order to confirm that TRPM7 
and Trim63 are targets of miR-381, Western blot analysis will be performed to 
determine the protein level in KI mice in which miR-381 is upregulated 
In conclusion, the results of the presented project suggest that the KI mouse model 
is a better NM mouse model than the previously described Tg mouse model, both 
from a phenotipic and a genetic point of view. It is evident that specific miRs are 
dysregulated (mainly upregulated) in NM and that they may influence the abnormal 
expression of genes that we highlighted in our analysis. However, in order to better 
understand this possible correlation, a deeper analysis needs to be performed. 
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APPENDIX A 
Genes altered in TA and DIA of 3-week-old males and 10-week-old males and 
females with fold ≥ 1.4 and pvalues < 0.05. Ratio indicate the fold change value. 
 
 
Table 1. Genes altered in TA of 3-week-old ACTA KI males  
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Table 2. Genes altered in DIA of 3-week-old ACTA KI males  
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Table 3. Genes altered in TA of 10-week-old ACTA KI males  
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Table 4. Genes altered in DIA of 10-week-old ACTA KI males  
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Table 5. Genes altered in TA of 10-week-old ACTA KI females 
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Table 6. Genes altered in DIA of 10-week-old ACTA KI females  
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